PMCID,ID,Label,Selected Text,Start,End,Valid Prompt
5771057,11690,significantly increase,"Results suggest that in the simple DT (M = 1.45) and moderate DT (M = 1.26) levels, participants were more accurate than in the complex DT (M = 1.16) levels.",43427,43639,True
4796457,12588,significantly increase,"The results is shown that after the intervention, ICIQ score has a significant difference between the two groups (P = 0.001). In other words, the training sessions improved the score in the experimental group versus control group.",20420,20651,True
3659039,12557,no significant difference,"Plasma PC ARA tended to decrease in the both groups (Figure 1). However, there were no significant differences from baseline in either group and there were no differences between groups at any timepoint.",19261,19504,True
4431716,12505,significantly decreased,The average hospitalization for the study group and control group was 13.8 (8.1) and 17.5 (14.5) respectively (p value <0.001).,36491,36619,True
1865086,11204,no significant difference,"visceral fat area declined 23.9 ± 7.4 cm2 in GH group, mean difference from placebo: −28.1 cm2 (95% CI −49.9 to −6.3 cm2; p = 0.02).",5581,5763,True
5836868,13370,significantly decreased,"From baseline to the end of the study, there was a consistently significant relative reduction in HbA1c in the alogliptin group as compared with placebo in each baseline HbA1c category (Figure 1).",46321,46569,True
3488177,12963,no significant difference,"Patients in the tourniquet group had less overt bleeding (317 mL vs. 615 mL), but the total bleeding estimated by hemoglobin dilution at day 4 was only slightly less (1,184 mL vs. 1,236 mL) with a mean difference of –54 mL (95% CI –256 to 152).",4374,4619,True
1974799,11286,significantly increase,"Significantly, more patients taking rizatriptan achieved both PR and PF within 2 h after dosing than other oral triptans.",3959,4081,True
4312979,12777,no significant difference,"The pain intensity and attack duration tended to decrease in the active group compared with the placebo group during the first month of follow-up (P = .42 and P = .37, respectively).",49266,49482,True
5980265,13024,no significant difference,"There were no differences in UP, GFR, and NaFE between the fenoldopam and the placebo groups.",6463,6556,True
3131514,12757,no significant difference,"Finally, prednisolone treatment increased whole-body proteolysis during hyperinsulinaemia, which tended to be driven by prednisolone 30 mg (5 ± 2%; p = 0.06).",5521,5696,True
1619408,11528,no significant difference,A similar proportion of patients in the ibandronate/PSP group [371/542 (68.5%)] and alendronate group [381/513 (74.3%)] experienced at least one adverse event.,38018,38178,True
5844373,11749,no significant difference,"Median OS was 41.9 months (95% CI, 31.8 to 58.0) in the concurrent regimen group and 30.7 months (95% CI, 22.7 to 38.3 months) in the sequential alternating regimen group (HR 0.58 (95% CI, 0.34 to 0.97); P=0.036; figure 2).",29251,29512,True
4439020,12068,no significant difference,"The distribution of scores in the Stanford Sleepiness Scale differed in the treatment arm as compared to the control arm, and there was a difference in mean values (p = 0.015).",7321,7497,True
5747130,13289,no significant difference,"The mean procedure duration from skin incision to insertion of the tracheal cannula did not differ significantly (n.s.) between the groups, being 14.7 ± 11.0 minutes in the VST group vs. 10.6 ± 8.2 minutes in the bronchoscopy group in the ITT analysis, and 10.0 ± 4.8 minutes vs. 10.6 ± 8.2 minutes (n.s.) in the PP analysis, respectively.",22651,22990,True
1550632,11532,no significant difference,"no between-group differences in quit rates were observed in smokers in the precontemplation (OR=1.07, CI 0.36-3.14, P=.91) and preparation (OR=1.15, CI 0.97-1.37, P=.10) stages of change.",5803,6024,True
3488177,12964,no significant difference,There was no significant difference in morphine consumption.,4692,4752,True
1131903,11546,no significant difference,"0.76). When tested for report of false murmurs, the group using conventional stethoscopes had 12 correct and 8 incorrect responses. The group using the electronic stethoscope had 11 correct and 9 incorrect responses (p = 0.75).",17113,17341,True
4967511,12535,significantly increase,"Significant differences between groups were limited to the outcomecategory Motor Skills (Complex Reaction Ability, Spatial Orientation Skills, Coordination with Precision) which were higher in the intervention group (P < .05).",6291,6551,True
3672758,12012,significantly increase,"The Ki-67 mean change relative to baseline was -29.1% (P = 0.019) and -8.2% (P = 0.384) in the treatment and control arm, respectively. Between treatment groups, the change in Ki-67 was statistically significant (P = 0.029)",8532,8806,True
387830,12367,significantly increase,The vitality measure showed a significant improvement for the celecoxib group (p = 0.012) but the magnitude of this effect was quite small.,31642,31781,True
3622234,12728,no significant difference,No difference in weight loss was seen between the two RT fractionation schedules (p = 0.839).,5034,5128,True
1794452,11330,significantly decreased,"This was related to a reduction of nosocomial pneumonia, which occurred in 16 (80%) patients versus seven (33%) patients, respectively (p < 0.001), and of ventilator-associated pneumonia from 13 to six episodes, respectively (p = 0.023).",6250,6527,True
4511442,13215,significantly increase,Weaning duration was shorter in the respiratory physiotherapy–driven weaning group (60 [50–80] minutes vs. 110 [80–130] minutes; p <0.001).,7871,8027,True
1440784,11486,no significant difference,"During 1–5 years of follow-up, children in the succimer group had systolic blood pressure 1.09 (95% confidence interval, 0.27–1.90) mmHg higher than did untreated children in a model with repeated measurements, but the difference in diastolic blood pressure was not statistically significant.",5236,5529,True
1974799,11290,significantly increase,"In the cumulative logit multivariate model, patients were 52% more satisfied when treating their attack with rizatriptan than when treating with another oral triptan (odds ratio 1.52, 95% CI: 1.25–1.85; p < 0.0001), after adjusting for treatment sequence, treatment order and the use of rescue medications. Of the 652 patients, who responded to the diary question regarding medication preference, 304 (46.6%) expressed a preference for rizatriptan, 220 (33.7%) preferred another oral triptan and 128 (19.6%) expressed no preference.",45559,46092,True
5777641,12481,significantly increase,"At the post-test period, compared to the controls, the participants in the experimental group reported significantly lower scores on the SCL-90 and on all dimensions except for sensitivity of interpersonal relationships and fear, higher scores on the MCMQ and the dimension of confrontation, higher IL-2 levels and lower cortisol levels (P< 0.05).",49290,49637,True
3531427,11745,no significant difference,"Low dose iloprost impaired VCO2 exercise (EDOM: −70 ml/min, 95% CI: −115–−26 ml/min, p = 0.004) whereas high dose iloprost did not alter VCO2 exercise (p = 0.90).",31063,31247,True
1134663,11878,no significant difference,"Comparing the TMS mappings before motor training in the individual subjects between memantine and placebo sessions, there was no significant difference in one of the mapping parameters, indicating a high reproducibility of the mapping procedure.",10552,10797,True
4707401,11929,significantly decreased,Intubation was significantly easier in group PS compared with group GS as measured by visual analogue scale (p=0.001),4785,4919,True
5984011,11706,no significant difference,"No significant difference was observed among the three groups regarding sexual satisfaction at the pre-treatment stage (p=0.204), and four (p=0.61) and eight (p=0.202) weeks after the intervention.",29192,29390,True
4712164,11804,no significant difference,"There was no statistically significant (P>0.05) flow mediated changes (Δ) of creatinine (0.23±0.27 vs. 0.38±0.33 vs. 0.26±0.18 mg/dL), MELD (1.25±5.72 vs. 1.70±2.18 vs. 1.45±2.21) or PRA (450.93±614.10 vs. 394.61±954.64 vs. 629.51±1,116.46 pg/mL).",5258,5525,True
59899,11379,significantly decreased,"The needlescopic group had a significantly shorter mean operative time (p = 0.02), reduced postoperative narcotics requirements (p = 0.05), shorter hospital stay (p = 0.04), and quicker return to work (p = 0.03) when compared with the laparoscopic group.",4495,4749,True
3376123,11868,no significant difference,At 12 weeks the incidence of mild POCD was significantly reduced in the intervention group (54% v 82% χ2 = 5.1 p = 0·02). The levels of moderate and severe POCD were not statistically different between the intervention and control groups at this juncture.,23654,23920,True
1931598,11263,no significant difference,"Second process half lifes were smaller with hot compresses, although not significant (p = 0.127).",14281,14378,True
4666408,12870,significantly decreased,Applying these data into a univariate Cox proportional hazard regression analysis showed reduced cardiovascular risk for those on active treatment (HR: 0:51; 05%CI 0.27–0.98;P = 0.04).,38494,38695,True
1820788,11209,significantly decreased,"The addition of artesunate significantly decreased gametocyte carriage on Day 4 (OR = 0.1 95% CI 0.02–0.6), Day 7 (OR = 0.2 95%CI 0.04–0.9), Day 14 (OR = 0.09 95% CI 0–0.8), and Day 21 (OR95%CI 0–0.9).",4472,4674,True
3626633,12464,no significant difference,"Body weight (kg)
−2.2 ± 1.4 b
−1.7 ± 1.2
0.16
−3.3 ± 1.6
−3.3 ± 1.4
0.94
−4.1 ± 1.8
−3.5 ± 1.9
0.25",6333,6875,True
29053,13253,significantly increase,"Table 4 shows the evolution of inspired RH and AH over the 24-h study periods. With regard to both RH and AH, the HH achieved the best performance when compared with the other two devices (P < 0.001).",15700,15956,True
4511442,13214,no significant difference,Total duration of mechanical ventilation (3.5 [2.0–7.3] days vs. 4.1 [2.7-7.1] days; p =0.467) and extubation failure (2 vs. 2; p =1.00) were similar between the two groups.,7660,7870,True
4173573,12644,significantly increase,"The emergence behaviour score of group R was 3.5 ± 0.4 min and that of groups RM and RD was 1.6 ± 0.3 and 1.5 ± 0.3 min, respectively (P < 0.001) [Table 2].",15153,15369,True
5844373,11750,no significant difference,"Updated response rates were similar in both groups (90.2% and 82.1%, respectively; P=0.34).",12587,12678,True
5758851,12007,significantly decreased,"The mean concentration of IFN-γ was 7.73 ± 0.75 pg/mL in the 0.1% CO group. This was significantly lower than the concentrations in the EDE, BSS, and 0.001% CO groups (14.54 ± 1.00 pg/mL, 12.84 ± 0.72 pg/mL, and 11.24 ± 0.74 pg/mL and P < 0.01, P < 0.01, and P = 0.03, resp.).",32524,32875,True
4504059,12377,no significant difference,Both weight and body mass index did not alter statistically from baseline in either of the groups as well as demonstrated no difference statistically on comparison (P > 0.05).,4902,5098,True
4393831,11949,significantly increase,Success	44/50 (88.0)	25/25 (100)	19/25 (76.0)	0.022,21976,22267,True
4707005,13324,no significant difference,"Success rate was 73.7 % vs. 71.4 % at six months and 72.2 % vs. 68.4 % at 12 months in the injection group and the control group respectively. No significant difference was noted between the two groups (six months: P = 0.87, 12 months: P = 1.00).",5709,5989,True
1574360,11452,no significant difference,"The effects of the intervention were sustained over consecutive shopping episodes, and there was no difference in the average cost of the food bought by each group.",5809,5973,True
3714433,12569,significantly increase,"The total dose of GnRH antagonist was significantly lower in group B than group A (2.5±0.9 vs. 3.2±0.8 ampoules, p<0.05).",5321,5459,True
1065073,12920,no significant difference,"However, there was no significant difference in 'mortality' between AV-ECMO and CMV groups within the 6-hour period of study (P > 0.05, Fisher's exact test).",25296,25473,True
1240403,11292,no significant difference,"There were 2,669 cases of highly credible gastroenteritis (HCG) during the study (0.80 cases/person/year). The ratio of HCG episode rates for the real WTU group compared to the sham WTU group was 0.99 (95% confidence interval, 0.85-1.15, p = 0.85).",2177,2426,True
3580671,12419,significantly decreased,Meropenem-related ICU stay was shorter in the Infusion group compared to the Bolus group (10 (7 to 14) days vs. 12 (7 to 19) days; P = 0.044),6139,6297,True
5856421,12924,no significant difference,"Other parameters, such as analgesic required on postoperative Day 1 (3.2 vs. 3; p = 0.67), VAS scores on Day 0 (4.55 vs. 4.65; p = 0.59), VAS scores on Day 1 (2.3 vs. 2.2; p = 0.84), superficial SSI (15% vs. 10%; p = 0.63), intraoperative GB perforation (30% vs. 20%; p = 0.71), and intraperitoneal drain (30% vs. 20%; p = 0.71) did not significantly differ between the groups.",6839,7216,True
535936,12877,no significant difference,"There were no differences in performance as measured by means or average rank. Despite technical problems, the students who viewed the digital lectures overwhelmingly felt the digital lectures could replace live lectures.",4387,4608,True
5816528,11763,significantly decreased,Also the overall canine retraction duration was significantly reduced in the experimental side as compared with control side in both groups about 25% (p ≤ 0.001).,6575,6758,True
5777928,12969,significantly increase,EDOF was significantly better than AOMF and AOP for HCVA averaged across distances (p ≤ 0.038),5658,5769,True
30713,11169,no significant difference,"There was a tendency for the ratio of partial pressure of arterial oxygen to fractional inspired oxygen concentration (PaO2/FIO2) to increase (174 ± 31 versus 188 ± 36; P = 0.068) and for the ratio of deadspace to tidal volume (Vd/Vt) to decrease (0.62 ± 0.18 versus 0.59 ± 0.18; P = 0.19) during periods of CLR, but these differences did not achieve statistical significance.",4545,5044,True
4526972,12453,significantly increase,"At t2, the intervention group showed significantly better adherence to the algorithm and temporal demands, and better procedural quality of PBLS in objective measures than did the control group.",8954,9149,True
1865086,11207,no significant difference,"However, mean glycohemoglobin levels for all groups did not change significantly during follow-up.",39023,39121,True
3682809,12619,no significant difference,"Weight, kg	176	0.1 (5.8)	156	−0.7 (9.4)	.31	.39",47120,47521,True
3682809,12619,no significant difference,"Body mass index, kg/m2	175	0.0 (2.1)	156	−0.2 (3.3)	.30	.36",47604,48029,True
3682809,12619,no significant difference,"Systolic blood pressure, mm Hg	174	0.9 (18.0)	163	−0.7 (17.3)	.74	.98",48112,48535,True
3682809,12619,no significant difference,"Diastolic blood pressure, mm Hg	174	−2.2 (9.9)	163	−1.1 (9.4)	.31	.59",48618,49041,True
3682809,12619,no significant difference,"High density lipoprotein cholesterol, mg/dL	169	−2.2 (9.6)	158	0.5 (10.5)	.50	.20",49124,49559,True
3682809,12619,no significant difference,"Low density lipoprotein cholesterol, mg/dL	143	−9.6 (28.8)	137	−3.0 (23.0)	.45	.14",49642,50078,True
3682809,12619,no significant difference,"Total cholesterol, mg/dL	174	−9.8 (29.4)	161	−2.9 (25.4)	.83	.15",50161,50579,True
3682809,12619,no significant difference,"Triglycerides, mg/dL	172	6.6 (93.0)	160	−4.4 (96.5)	.58	.33",50662,51075,True
3700147,13128,significantly decreased,"the mean scores for 3 days post-operatively for the experimental group and control group are 3.5 and 5.1, respectively, with P-value of 0.001 which is highly significant.",14460,14647,True
4733222,12653,significantly increase,"Participants in ePaper conditions had a much higher frequency of guessing while reporting as compared with those in Mobile conditions—χ1 2=25.25, P<.001 (N=63).",7411,7613,True
3698202,12714,no significant difference,"There was a significant time effect for quadriceps and biceps thickness (p < 0.05), which increased from pre to post training in the rice protein (5.0 ± 0.4 to 5.1 ± 0.4 to 5.2 ± 0.5 cm and 3.6 ± 0.3 to 3.9 ± 0.3 to 4.1 ± 0.4 cm, respectively) and whey protein (4.8 ± 0.7 to 5.0 ± 0.5 to 5.1 ± 0.5 cm and 3.6 ± 0.2 to 4.0 ± 0.3 to 4.1 ± 0.3 cm, respectively) conditions, with no differences between conditions (no condition X time effect).",27479,27919,True
3525027,12554,no significant difference,There was no significant difference in HCO3 values in different time intervals among three groups (P > 0.05).,5554,5683,True
3935224,12129,significantly increase,There were significant improvements in cognition [COGNISTAT (Neurobehavioral Cognitive Status Examination) and MMSE (Mini-Mental State Examination)] for the treatment group compared with the control group (p < 0.01).,5565,5798,True
1693563,11420,significantly increase,The intensity of dyspnea was significantly greater (p < 0.05) in the asthmatic subjects.,4179,4267,True
3558644,12127,significantly increase,"The overall incidence of withdrawal movements after rocuronium was 34.3% with lidocaine (P = 0.001), 40% with ketorolac (P = 0.004), and 8.6% with both (P < 0.001), compared with 74.3% with placebo.",4691,4889,True
5835557,11790,no significant difference,The occurrence of 74 adverse events (AE) was comparable between groups. The most common AE was flu-like symptoms.,7063,7177,True
1863515,11603,significantly increase,"During the second period, between the 35-wk visit and delivery, after adjustment, the haemoglobin level, leucocyte count, and absolute neutrophil count increased significantly faster in women randomized to the long regimen than women in the short regimen, as shown by the mean (95% CI) increase associated with exposure to zidovudine of 0.1 (0.0 to 0.1) g/dl/wk, p < 0.001, 105 (18 to 191) cells/mm3/wk, p = 0.02, 147 (59 to 234) cells/mm3/wk, p = 0.001, respectively.",28115,28660,True
5569270,13053,significantly decreased,"Except from a statistically significant group difference in the second peak knee flexor moment and second peak vertical ground reaction force, there were no group differences in the analysed gait variables as presented in table 2.",42708,42977,True
1584256,11517,no significant difference,"The hazard ratio for myocardial infarction/coronary death with estrogen plus progestin was 1.13 (95% confidence interval 0.68–1.89) among non-users of COX inhibitors, and 1.35 (95% confidence interval 0.86–2.10) among continuous users.",7764,7999,True
5812983,12040,significantly decreased,"However, per-protocol analyses found a greater decrease for the CancerCope group in psychological distress (P=.04), cancer-specific distress (P=.02), and unmet psychological care needs (P=.03) from baseline to 8 weeks compared with the patient education group.",11283,11595,True
3767897,11717,significantly increase,"On the clinical assessment, the mean VAS score was significantly different immediately after surgery between group I and group II (5.7 vs. 4.5; p=0.006), but showed no significant difference thereafter.",17389,17591,True
1488896,11909,no significant difference,"The increase in disability was not significantly different between study groups (0.08 points; 95% CI, −1.1–1.2; p = 0.75).",5917,6059,True
2667135,12633,significantly increase,"CoPAT patients received longer courses of study antibiotics with a mean of 25.4 days (range 9–74 days) compared with 13.5 days (range 1–43) in the IPAT group (P < 0.001), and a higher proportion of CoPAT patients completed therapy as part of the study (90.3% versus 45.4%, P < 0.001).",30902,31223,True
4331444,12978,no significant difference,"NT-proBNP increased following chemoradiotherapy (p = 0.05) but not after chemotherapy (p > 0.99), and there was a trend towards an interaction effect (p = 0.07).",6790,6952,True
3575558,11777,no significant difference,"There were no significant differences in leak, AHI reduction, and optimal CPAP pressure, even in patients with significant naso-pharyngeal symptoms.",4840,4988,True
3672764,13145,no significant difference,"For the secondary endpoints of mean change in pain at 24, 48, and 72 hours (Figure 3), the trends in pain reduction among the three treatment groups were similar when pain was assessed using the Likert scale and the NRS; no significant differences were observed with rilonacept plus indomethacin relative to indomethacin monotherapy, but indomethacin monotherapy was significantly superior to rilonacept monotherapy at all time points (P < 0.05).",27790,28290,True
5773984,12620,no significant difference,"There were no occlusal discrepancies throughout the period of 1st postoperative day to 3rd postoperative month in Group A, whereas in Group B, very mild occlusal discrepancies was noted in 4 cases (40%) 1st postoperatively day with P = 0.171 and in 3 cases (30%) 1st postoperatively month with P = 0.317. There was no statistically significant difference among any period in both groups [Graph 5].",13257,13769,True
3622234,12729,significantly decreased,"However, significantly more patients treated with AF were reported to have swallowing problems (AF 56.9%, CF 43.1%, missing n = 38), mucositis (AF 54.2%, CF 45.8%, missing n = 51) and used opioid analgesics (AF 58.6%, CF 41.4%, missing n = 39) more frequently at the end of RT (p < 0.001, 0.001 and 0.001, respectively).",15738,16058,True
3544627,13187,significantly increase,"Post hoc testing revealed that in the slow condition, hunger was significantly higher at 5, 10, 15, and 20min (p < 0.001) and was significantly lower at 60min (p = 0.003) compared with the fast condition, as shown in Figure 2A.",28896,29173,True
4689556,12869,no significant difference,"ere we found no difference in the number of prescriptions issued for medicated skin creams (median 1.0 IQR 0.0, 2.0 combined vitamin D versus 0.0 (0.0, 2.0) controls; p = 0.27) or wheezing medications (median 0.0 IQR 0.0, 1.0 combined vitamin D versus 0.0 (0.0, 0.0) controls; p = 0.42).",87424,87711,True
3744465,12517,no significant difference,"For PSPC and placebo groups, 3-d averages during 7.5 h running for heart rate (HR) were 152±15.3 (82.1±3.6% HRmax) and 151±9.7 bpm (84.2±3.6% HRmax), respectively, (P = 0.930), oxygen consumption (VO2) were 37.8±3.9 (66.5±7.2% VO2max) and 36.5±3.2 ml.kg−1.min−1 (67.8±7.9% VO2max), respectively (P = 0.326), rating of perceived exertion (RPE) were 13.5±1.3 and 13.0±0.8, respectively (P = 0.300), distances run were 25.3±2.9 and 25.0±2.1 km/day, respectively (P = 0.777), weight changes were −1.8±0.9 and −1.5±0.7 kg/day, respectively (P = 0.327), and plasma volume shifts were −2.00±0.08% and −2.00±0.07%, respectively (P = 0.982).",48131,48852,True
5777641,12483,significantly decreased,"Compared with the controls, patients in the intervention group had a better mental state and coping style (confrontation), higher levels of IL-2 and lower levels of cortisol (all P<0.05).",12798,13005,True
4913995,13348,significantly increase,The mean of score changes for sexual attitudes and traditional perceptions in the intervention group was significantly higher than that in the control group (P<0.0001).,4512,4697,True
4021157,12655,no significant difference,The differences between the groups in the total number of antenatal visits received after 20 weeks gestation were small and not statistically significant (p = 0.74);,33392,33557,True
4702321,13194,significantly increase,"The largest treatment effect was found on the Respiratory Symptoms scale with a mean improvement of 5.9 points observed among patients receiving ivacaftor, exceeding the MCID value of 4 points, vs. a mean decline of 2.7 points among those receiving placebo (treatment effect of 8.6 points, P < 0.001) [12].Table 1",22147,22549,True
1805771,11257,no significant difference,"Participants responded more positively to the statement ""I believe this treatment would allow me to get better quicker"" for the HVLA treatment. There were no statistically significant differences between responses for HVLA and ULTRA (p = 0.136) or between ULTRA and LT (p = 0.231).",23940,24223,True
32174,11174,no significant difference,"More PHR than control group patients felt ready to go home at the point of discharge (82% vs. 60%, p=0.14),",23970,24078,True
3714436,12340,no significant difference,"At 15 months (n=411), adjusted mean change in UPDRS total score showed no significant difference between early and delayed pramipexole (−0·4 points, 95% CI −2·2 to 1·4, p=0·65).",6493,6671,True
1863514,11306,significantly increase,"However, participants consuming Sutherlandia reported improved appetite compared to those in the placebo group (p = 0.01).",6171,6331,True
59604,11200,significantly increase,Losartan was also tolerated significantly better.,5911,5960,True
3701833,12741,significantly decreased,"The gel, when delivered to the sites with oxidative stress, was effective in increasing clinical attachment and in reducing gingival inflammation, probing depth, and 8-OHdG levels as compared to the placebo and sham sites.",4882,5104,True
3257955,12169,no significant difference,"There was no significant change in spirometry values (FEV1 or FVC) with HFCWO baseline FEV1 1.05 (SD 0.37) versus postintervention FEV1 1.07 (SD 0.38) L or in the conventional phase (baseline FEV1 0.97 [SD 0.37]) versus postintervention (FEV1 1.01 [SD 0.36] L, P = not significant), as shown in Figure 2.",13285,13709,True
1190216,11237,no significant difference,The diameter of the largest follicle at the time of treatment did not differ among groups (P = 0.9).,14916,15017,True
5838771,12717,significantly decreased,here was a significantly greater increase in serum IL-6 levels in the Ligasure group at 24 hours (p=0.010).,5447,5554,True
4431716,12508,no significant difference,"There were no perinatal deaths in either group. The survival rate at discharge was 100% in both groups. A drop-out analysis showed that the rate in the study group was 2.2% (8/360) compared to 4.7% (17/360) in the controls (X2 = 3.36; RR = 0.47; 95% CI 0.21–1.08; z = 1.76, p = 0.07). Moreover, no morbidities and/or complications were observed after the application of OMT.",45304,45689,True
4590707,13137,significantly decreased,"In response to treatment, the women in the melatonin group rated with insomnia reduced their score by −37.5 % (IQR: −64.5;−15.5) compared with −13.3 % (IQR: −32.1;9.4) in the placebo group (p = 0.08 for between group changes).Table 4",30113,30392,True
5985893,12439,no significant difference,"There were no statistically significant differences in incidences of postpartum haemorrhage (p = 0.119), Puerperal, pyrexia (p = 0.943), low birth weight (p = 0.556) asphyxia (p = 0.706) and perinatal death (p = 0.621).",5011,5230,True
4359698,13245,significantly increase,Both HRR and rMSSD30s were significantly greater during recovery from the cycling CPET compared to the walking and running CPETs (P < 0.001).,5026,5198,True
115849,11583,significantly increase,"Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p<0.05).",6382,6535,True
1705535,11326,significantly decreased,Analysis of first treatment phase data from one study (n = 793) showed that the incidence of psoriatic arthropathy per patient-year was lower in efalizumab-treated patients (0.10; 95% CI 0.05–0.18) than in those given placebo (0.17; 95% CI 0.08–0.30).,4187,4456,True
1540413,11315,no significant difference,"The antibody titers in groups C and D (IM and ID routs with using of Levamisole) were 541.1 ± 494.4 IU/L and 297.2 ± 9 IU/L (p = 0.6), respectively.",12257,12405,True
3630066,12611,significantly decreased,"In the first experiment, CO2 reduced pain ratings only minimally by 5.3% compared to air if given alternatingly with significant results for the main factor GROUP (F1,47 = 4.438; p = 0.041) and the interaction term TIME*GROUP (F2.6,121.2 = 3.3; p = 0.029) in the repeated-measures ANOVA.",4695,5016,True
5834147,12429,no significant difference,"Stroke or systemic embolism	Absent	1.03 (0.76–1.39)	0.8704	0.0246	0.69 (0.50–0.97)	0.0329	0.2734
Present	0.54 (0.33–0.87)	0.0106		0.50 (0.30–0.81)	0.0053		
Any stroke	Absent	1.04 (0.76–1.43)	0.1757	0.0309	0.70 (0.50–1.00)	0.0494	0.1626
Present	0.64 (0.38–1.07)	0.0903		0.45 (0.27–0.76)	0.0026		
All-cause death	Absent	0.86 (0.70–1.07)	0.1773	0.9953	0.80 (0.65–1.00)	0.0471	0.5854
Present	0.86 (0.65–1.16)	0.3238		0.89 (0.66–1.18)	0.4197		
Vascular death	Absent	0.82 (0.62–1.08)	0.1595	0.7352	0.86 (0.65–1.14)	0.3058	0.6656
Present	0.86 (0.65–1.16)	0.3238		0.78 (0.56–1.10)	0.1611",48205,50799,True
5807505,12892,no significant difference,The participants performed equally well when presented with a “straight-forward” anatomy [Group A vs. Group B—time sec: 445.5 vs. 496 p = 0.64—NOM: 437 vs. 413 p = 0.88—PL cm: 1317 vs. 1059 p = 0.32—per: 0.5 vs. 0 p = 0.22—NCB: 0 vs. 0 p = 0.71—DVS: 0 vs. 0 p = 0.2];,5917,6286,True
2869037,12434,significantly decreased,Drug-related adverse events were significantly (p < 0.05) less under F (3 vs. 10).,4937,5036,True
5411411,13163,significantly decreased,The mean cecal intubation time was 209 s in group I and 224 s in group II (p < 0.05).,6826,6928,True
5801240,12223,significantly increase,The incidences of AEs related to GMIs were significantly greater in patients of both genders receiving ertugliflozin 15 mg or 5 mg (2.1–10.0%) than those receiving glimepiride (0–1.4%; Table 3).,43439,43674,True
1810515,11415,no significant difference,"There was no significant change in Tmax, AUC0-t or AUC0-∞.",4736,4827,True
5852975,11971,significantly increase,Improved social well being	2.69 ± 0.90	3.46 ± 0.81	0.04,38365,38459,True
3573541,12530,significantly decreased,"Healthy reduction in platelet count (twelfth to twentieth week) occurred in a higher (P < 0.001, Chi2 test) number of women in the yoga group than the control group. A similar trend was found in uric acid.",4838,5074,True
5758851,12005,significantly increase,Tear volume in the 0.1% CO treatment group was significantly greater than those in the other groups (all P < 0.01; Figure 4(a)).,30428,30615,True
5721487,12630,significantly increase,The improvement of AR symptoms in the group receiving NBS was significantly higher compared to control group (4.73 ± 1.84 vs. 0.38 ± 2.06; P < 0.0001).,6224,6392,True
4751201,11678,no significant difference,"PTU and PTG systems produced similar canal transportation at the straight part,",5484,5564,True
1969447,11619,significantly decreased,"For patients surviving 5 years from randomisation, subsequent survival favoured placebo over levamisole (100% vs 57%; P < 0.03).",2104,2233,True
5836873,12332,no significant difference,"No group differences were seen in PCS score, anxiety, self‐efficacy, or total healthcare costs.",10720,10867,True
1794625,11214,no significant difference,"APAP with C-Flex was as effective as CPAP, with no differences detected in sleep latency (17 ± 5 vs 12.3 ± 3 min, p = 0.4),",4061,4202,True
3510731,12234,no significant difference,Median time in seconds (interquartile range)	25.0 (37.2)b	25.3 (35.8)b,19744,19895,True
4569055,12987,no significant difference,"Thirty-six students show no better progress (beginning and final test means = 69.87 and 80.98 points out of 176 for the control group, 64.60 and 78.11 for the CPOE group, p = 0.556) during their rotation in either group, even after adjusting for each student and CR,",8419,8685,True
1968186,11276,significantly increase,"CMF caused more objective alopecia (P < 0.001), nausea and vomiting (P < 0.001) and haematological toxicity (P < 0.02).",2289,2408,True
5852975,11975,no significant difference,"MASRI (mean)	87.8 ± 4.0 (12)	90.4 ± 2.4 (12)	0.76	85.4 ± 6.7 (11)	84.2 ± 7.7 (11)	0.44*
MASRI ≥0.8	79% (11/14)	93% (13/14)	0.28	75% (9/12)	75% (9/12)	1.0",31209,31475,True
3698202,12712,no significant difference,"There was a significant time effect (p <0.01) for lean body mass, which increased in both the rice (58.5 ± 5.5 (baseline) to 59.5 ± 4.5 (week 4) to 61.0 ± 5.6 kg (week 8) and whey protein (59.6 ± 5.2 to 61.9 ± 4.5 to 62.8 ± 5.2 kg) conditions, with no differences between conditions (no condition X time effect).",26824,27137,True
5984011,11704,no significant difference,he three groups were not significantly different in terms of orgasm before treatment (p=0.08) and four weeks after the intervention (p=0.902).,27618,27761,True
5732479,12172,no significant difference,"Likewise, the proportion of subjects that displayed seroconversion was similar between groups [10 out of 13 (77%) in the LPS–Fluenz group and all 13 subjects in the placebo–Fluenz group, p = 0.22].",39948,40162,True
3680656,12357,no significant difference,"At endpoint (week 24, last observation carried forward), memantine-treated patients significantly outperformed placebo-treated patients on the SIB (least squares mean difference [95 % CI] 2.6 [1.0, 4.2]; p = 0.001), CIBIC-Plus (p = 0.008), NPI (p = 0.005), and verbal fluency test (p = 0.004); the effect did not achieve significance on ADCS–ADL19 (p = 0.177).",6222,6696,True
88884,11180,no significant difference,(1) Smoking causes bad breath ....................	98.4	100	N.S.	99.7	N.S.,23272,23461,True
5038098,11957,significantly increase,"When the results were evaluated according to severity of acne, in cases of severe acne a statistically significant difference in response rate was noted between both groups (Group A better than Group B) during the whole study period (P value < 0.005 at each follow up) [Figure 2],",13684,14021,True
1569640,11424,no significant difference,"A small increase in mean body weight of less than 0.5 kg was observed in both groups, but the changes from baseline were not significant in either case and there was no significant difference (P = 0.879) between treatments (data not shown).",22712,22969,True
5741924,12311,no significant difference,"There were also no differences between the two groups in mean gestational weight gain, gestational diabetes, birth weight, infant length, and head circumference.",8693,8854,True
3046499,11754,significantly decreased,"Also, patients receiving haloperidol had significant correlation between blood lactate and dystonia at 1 month (P < 0.001) and 6 months (P = 0.012)",5020,5205,True
5758851,12008,significantly decreased,"The mean levels of IP-10 were 15.66 ± 0.51 pg/mL, 15.14 ± 1.12 pg/mL, and 13.98 ± 0.32 pg/mL in the 0.001%, 0.01%, and 0.1% CO groups, respectively, after 7 days of desiccating stress. The 0.1% CO group showed significantly lower levels than the EDE and BSS groups (22.23 ± 1.15 pg/mL and 19.21 ± 0.89 pg/mL, P = 0.02 in both case). The 0.001% and 0.01% CO groups showed significantly lower levels than the EDE group (P = 0.02, P < 0.01).",33101,33590,True
3659004,13398,no significant difference,"As shown in Figure 4, the difference in response after occlusion in blood flow between US-born Asians and Caucasians (panel A) was eliminated after 2-week administration of Coq10 panel B (p>0.05, ANOVA).",24487,24747,True
3658908,12030,no significant difference,"There was no significant difference between Group I and Group O with respect to the change in lesion score in the esophagus, stomach, and duodenum before and after treatment.",6387,6561,True
1434781,13381,significantly increase,The mean size of the posterior capsulorhexis was 4.6 ± 1.77 mm and 4.0 ± 0.93 mm in the group 1 and 2 respectively (p = 0.04) (Table 1).,11378,11553,True
5729492,12664,no significant difference,"At the 4‐month follow‐up, there was no significant difference in VFA reduction between the control and feedback groups (−4.4% vs. −3.0%; 95% CI, −3.8 to 5.5).",7282,7440,True
5769198,12116,significantly increase,"At the end of 5 years, mental health (P = 0.05), perceived stress (P = 0.01), and negative affect (NA) (P = 0.05) have shown significant improvements. WHO-QOL BREF score has shown improvements in physical health (P = 0.046), environmental health (P = 0.04), perceived stress (P = 0.001), and NA (P = 0.02) in YLSP than CLSP",4811,5253,True
1586021,11362,significantly increase,"The proportion of men with presumed early recanalization was 25% (95% CI 21%–30%) with ligation and excision without FI, 10% (95% CI 7%–13%) with ligation and excision with FI, 9% (95% CI 5%–13%) with electrocautery without FI, and 0% (95% CI 0%–2%) with thermal cautery with FI.",22153,22432,True
4980729,12051,no significant difference,"During exposure in the pollen challenge chamber, the nasal discharge score increased over time and was ≥1 after 165 minutes in the placebo group. In the pranlukast group, the score was one scale below that of the placebo group. After subjects left the chamber, the score increased continuously until the following morning in the placebo group, but tended to decrease in the pranlukast group (1.179 vs. 0.821, p = 0.106) (Figure 3).",18522,19010,True
3917487,13108,significantly decreased,The intervention group complained of dyspnea for 2.4 days and the value for the controlwas 4.4 days (p=0.024).,5235,5345,True
3666902,12081,significantly increase,"Compared to placebo, patients in the olanzapine group experienced greater improvement in the primary outcome measure, MADRS total score (−14.9 vs. −10.7; p = .01).",5730,5894,True
4644316,12348,no significant difference,"In the experiment group, the pain score with a mean of 0.28 (± 0.89) was lower than that of the control group (0.49 ± 1.17), but this difference was not significant (P = 0.25).",24483,24660,True
4707401,11928,no significant difference,No significant differences between both groups regarding the total intubation time (p=0.08) was observed.,4662,4785,True
1702540,11347,significantly increase,The estimation error (the absolute value of the difference between estimated and measured glucose) in the hungry trained group (2.6 ± 1.9 mg/dL; 3.2 ± 2.4% of the measured value) was significantly lower than that in the hungry control group (14.9 ± 9.8 mg/dL; 16.7 ± 11.0%; Table 2; Figure 3).,25740,26109,True
1794254,11231,significantly increase,URO transiently increased urine sodium excretion from 22 ± 16 μmol/min (mean ± SD) to 78 ± 41 μmol/min (P < 0.05) and there was no effect of placebo (29 ± 14 to 44 ± 32).,4085,4255,True
3743070,12942,significantly decreased,"BAY 94-8862 was associated with significantly smaller mean increases in serum potassium concentration than spironolactone (0.04–0.30 and 0.45 mmol/L, respectively, P < 0.0001–0.0107)",7631,7830,True
1173136,11497,no significant difference,"However HDL, LDL and cyclosporine serum levels had no significant differences by both of swallowing and chewing routes.",5095,5230,True
29047,11554,significantly increase,Interestingly the arterial partial oxygen tension (PaO2) : fractional inspired oxygen (FIO2) ratios were statistically significantly higher in the dexmedetomidine group.,2462,2654,True
5850960,12696,no significant difference,"Th1-biased PAP-specific T-cell responses were detected in 11/18 individuals, and were not statistically different between study arms.",5424,5557,True
5313491,12148,no significant difference,"Hospital length of stay and costs, as well as mortality at 30 day, were not significantly reduced.",5618,5716,True
4469426,12397,significantly increase,"The addition of almonds to the CON diet increased plasma α-tocopherol status by a mean of 5.8 %, reflecting patient compliance (P ≤0.05)",6007,6143,True
4439020,12069,no significant difference,No difference between patients in treatment arm and control arm was observed for the Stroop test.,7223,7320,True
1821024,12151,significantly increase,"Significantly more patients treated with hydrotherapy (40/46, 87%) were much better or very much better than the patients treated with land exercise (19/40, 47.5%), p < 0.001 Fisher's exact test.",4995,5190,True
1388215,11643,no significant difference,"Although no significant difference was demonstrated between the 4 and 6 weeks regimens, there was a trend observed, in that, microfilarial reduction appeared to have been greater following the 6 weeks regimen.",5289,5498,True
3606470,12844,significantly increase,The completion rate for the 78-week double-blind extension period was lower for the placebo group (63.5%) than for the dapagliflozin groups (68.3% to 79.8%).,5386,5543,True
4021157,12656,no significant difference,The differences between the groups in the total number of antenatal visits received after 20 weeks gestation were small and not statistically significant (p = 0.74); the numbers of routine and unscheduled visits were also similar in the three groups (Table 3).,33392,33691,True
5642889,13299,no significant difference,"As the primary outcome, the mean total blood loss up to 2 h after delivery was not reduced in the intervention group, compared with the control group (513.3 vs. 478.1 g, respectively, MD = 35.2 g, 95% CI = −65.3–135.7).",38414,38633,True
1804280,11562,no significant difference,The average cost per patient was not significantly different between the intervention and control groups.,6479,6584,True
1216327,11267,significantly increase,"The duration of the illness was longer in the infants fed juice as compared with those given WA (p = 0.006), the mean +/- SD duration in hours was 49.4 ± 32.6, 47.5 ± 38.9 and 26.5 ± 27.4 in patients fed AJ, WGJ and WA respectively.",4913,5146,True
4771973,11995,significantly decreased,"HbA1c was more reduced in the metformin group (between-group difference −0.42% (95% CI −0.62% to −0.23%), p<0.001)), despite the significantly lower insulin dose at end of trial in the metformin group (1.04 IU/kg (95% CI 0.94 to 1.15)) compared with placebo (1.36 IU/kg (95% CI 1.23 to 1.51), p<0.001).",12359,12673,True
3636841,12306,significantly decreased,The mean cavity entrance size with group A was 0.98133 mm and group B was 0.26083 mm (P < 0.001).,3820,3934,True
3257955,12170,no significant difference,"Sputum expectoration remained individually variable but showed a trend toward a reduction after HFCWO. In the HFCWO phase, the mean change in sputum volume was −2.6 mL (range −53 to +27 mL), and in the conventional phase the mean change was +6 mL (range −70 to +40 mL), P = 0.06.",13716,14012,True
3558644,12128,no significant difference,There was no significant difference in withdrawal movement between the lidocaine group and the ketorolac group.,5295,5406,True
3757803,11966,significantly decreased,The modified Children's Hospital of Eastern Ontario Pain Scale was significantly lower in group D compared to group C and group P.,4350,4480,True
5861369,12575,no significant difference,"Escitalopram had no significant effect on measures of insulin sensitivity, insulin secretion, fasting lipids, mental health or HRQoL.",5386,5519,True
5791430,12723,no significant difference,"The results show that there was not any significant difference between the knowledge scores of mobile health and workshop group before intervention, but there was a significant difference after 2-week intervention (P = 0.012).",4523,4766,True
4681166,12809,significantly decreased,"However, the whey protein group reduced more total and abdominal area fat when compared to the carbohydrate group independent of the type of RT (P < 0.05).",5486,5661,True
1550875,11391,no significant difference,"No significant difference was observed regarding the time course of temperature, leukocytosis or C-reactive protein level.",5030,5153,True
4689586,12773,significantly increase,The most striking difference between the drug conditions was an increase in cortisol concentration upon exposure to MDMA (p < 0.001) or MDMA/MPH (p < 0.0001) compared to placebo or MPH alone (Fig 1C).,21323,21594,True
4771973,11997,significantly increase,"The groups did not differ with regard to number of patients with severe or non-severe hypoglycaemic or other serious adverse events, but the metformin group had more non-severe hypoglycaemic episodes (4347 vs 3161, p<0.001).",12779,13003,True
3636841,12309,no significant difference,There was no statistical difference in the preference of treatment (P = 0.12).,4364,4459,True
1664572,11637,no significant difference,"The mean STAI-1 score filled in before PCC was 36.4 (95% confidence interval (CI) 35.4 – 37.3), and showed no difference between women who did and who did not actually attend PCC.",16999,17178,True
4713062,12336,significantly increase,"CaBF increased more rapidly and to a greater extent during a single SI (p = 0.01),",7805,7887,True
5853038,13263,significantly decreased,Meswak-based toothpaste resulted in significantly less plaque.,5240,5302,True
2855831,11981,significantly decreased,"After 7 days of treatment, the change in the BSS total score was significantly better in the 60 mg and 90 mg groups compared with placebo that of the without relevant differences between these two dosages. Especially ‘coughing’, ‘sputum’ and ‘rales at auscultation’ improved under EPs-7630.",4180,4471,True
3556314,12759,no significant difference,"Patients in the PEMF group showed a higher rate of union than those in the control group after the first three months of treatment, but this difference failed to achieve statistical significance.",5034,5230,True
5038098,11954,no significant difference,"At the end of therapy, decrease in the total acne loads up to 98.99% (Group A) and 97.69% (Group B) was achieved from the baseline (P < 0.01), excellent response was observed in 98.3% (Group A) and 93.96% (Group B) patients (P = 0.166).",4186,4460,True
88884,11192,significantly increase,What percentage of adults use tobacco every week ............................	4.4	49.1	p < 0.0001,36407,36573,True
3698199,12899,significantly decreased,"However, planned contrasts revealed that improvements for PTSD severity over time were only significant within the TAU + SWT group.",4648,4780,True
3781990,13081,significantly decreased,"Statistically significant differences in tumor size (T3; 31% in the control vs. 51% in the intervention group, p=.036) and distant tumor spread (M1; 18% in controls vs. 44%, p=.032) at the time of initial diagnosis were observed (Table 1).",19044,19322,True
1501010,11337,no significant difference,"At T1, the BPRS decreased in the experimental group (50.3 ± 21.1) and increased in the controls (58.4 ± 21.1) (t = 1.439, df = 57, p = 0.16).",28671,28813,True
4166055,12825,significantly increase,"but mean of SBP at min 10 and 15, mean of DBP at min 10, and mean of MAP at min 5 and 10 in hypertonic saline group was significantly more than the normal group (P < 0.05)",4227,4418,True
4518420,12325,significantly decreased,"Ksharasutra group took more time to heal (mean: 53 vs. 35.7 days, P = 0.002) despite reduced disruption to their routine work (2.7 vs. 15.5 days work off, P <0.001).",5219,5418,True
2367663,13282,no significant difference,"Finally mean concentrations of malathion residue in house dust decreased from year 1 to year 4 in both intervention and control communities; however, there were no significant differences between communities after adjusting for year, p = 0.43.",42115,42375,True
1334191,11442,significantly increase,"Of the USFAs, higher levels of C18:1 MUFA, C20:4 and C22:6 long chain PUFA on high-USFA diet lead to higher C18:1, C20:4 and C22:6 within RBCs (ANOVA, time*diet, P < 0.05).",5126,5299,True
4914313,13407,no significant difference,Patients with high baseline plasma miR-21 had worse PFS (3.5 vs. 12.7 months; p:0.032) and OS (5.1 vs 15.3 months; p:0.5) compared to patients with low miR-21.,6891,7088,True
5777645,12290,significantly increase,"Mean BMI change was -1.65 kg/m2 (SD = 2.5; CI95%: -2.25; -1.06) in the intervention group and +0.05 kg/m2 (SD = 3.2; CI95%: -0.71; 0.81) in the control group, p = 0.0005.",13283,13453,True
3658908,12033,significantly decreased,"In addition, fecal occult blood levels increased significantly in Group O (p = 0.0018), but there was no change in Group I (p = 1.0), and the between-group difference was significant (p = 0.0031).",7333,7529,True
4393831,11948,significantly decreased,"At the time of discharge, pulmonary artery pressure was significantly higher in the anticoagulant-alone group than in the thrombolytic-plus-anticoagulant group (p value = 0.018);",5102,5281,True
4713062,12337,no significant difference,There were no differences in CaBF or cerebral oxygen delivery between the multiple SI and no SI lambs.,8190,8292,True
5557991,11782,no significant difference,"Despite higher success of sedation with ketamine compared to midazolam, no significant differences were found between the two regarding patients’ overall behavior (P>0.05).",4768,4940,True
88884,11185,significantly increase,It was also found that retention on two knowledge items 'recognition that smokers have yellow teeth and fingers' and 'smoking one pack of cigarettes a day costs several hundred dollars per year' was maintained for four months.,4942,5168,True
5762805,12583,significantly decreased,revision thyroidectomy was necessary in 1 (0.6%) TT versus 5 (2.8%) DO versus 14 (8.0%) BST patients (p < 0.001).,5369,5502,True
3717762,13287,no significant difference,There were no clinically significant between-group differences in vital signs.,38365,38443,True
4601415,12830,no significant difference,No significant difference in evaluation was observed 1 month after treatment (P = 0.56).,5785,5891,True
34516,11537,significantly increase,Following oral methionine tHcy concentration increased significantly versus placebo.,4673,4758,True
1550405,11316,significantly decreased,"The overall FSH dose needed to achieve ovulation was significantly lower with r-FSH,",5099,5183,True
5980265,13023,no significant difference,"The proportion of dogs with AKI did not differ between the fenoldopam and the placebo groups (9/20; 45% versus 13/20; 65%, respectively; P = .204).",6298,6462,True
4748323,11774,significantly decreased,"The reduction in time for 10 m walking while counting backwards by three was more pronounced in the intervention than the control group (F1,127 = 4.32, p = 0.040).",34614,34805,True
4173564,13090,significantly decreased,"In group N, mean values of BP after an initial decrease until 5 min after the study drug showed a clinically significant rise at IAETI (maximum) and until 3 min thereafter, but fell below the mean basal values at the end of the study period. In group P, a continuous increase from mean basal values of BP were recorded throughout the study period maximum being at IAETI and remained well above the mean basal values at the end of the study period [Table 2].",12389,12885,True
3668608,12926,significantly decreased,"Furthermore, dropout rates were significantly higher for participants assigned to MoodGYM (451/613, 74%) compared with IPT (414/620, 67%) or CBT (429/610, 70%; χ2 2= 6.8, P=.03).",32477,32694,True
5001793,13307,significantly decreased,"During the 24 hours after surgery, morphine consumption in the ILI+IHG group decreased compared with the TAP group, as well as in each “block” group versus the control group.",6196,6371,True
4272222,13126,no significant difference,"Safety parameters, including adverse events and vital signs, were similar for SSTS and placebo.",5641,5736,True
3664406,13556,no significant difference,"Wash was noninferior to water alone in terms of TEWL (intention-to-treat analysis: 95% confidence interval [CI] for difference [wash–water, adjusted for family history of eczema, neonate state, and baseline] −1.24, 1.07; per protocol analysis: 95% CI −1.42, 1.09).",6080,6344,True
3093782,12210,significantly decreased,"With both statistical approaches, intense intermittent and moderate continuous exercises were both effective in reducing postprandial triglycerides; however, only intense intermittent exercise reduced the levels of postprandial very low density lipoprotein",5557,5813,True
4170701,13502,no significant difference,"On the follow-up of disease activity and functional ability, no significant statistical difference was found between the two groups in ESR, CRP, Hb, grip strength, BAS-G, BASFI, and BASDAI, either at baseline or after 3-month exercise (Table 5).",28810,29096,True
4722945,11713,no significant difference,"Vomiting occurred after 13 (17%) intranasal and 9 (12%) intramuscular administrations; nausea without vomiting occurred during an additional 14 (18%) intranasal and 20 (26%) intramuscular administrations (P = 0.59) (nausea, with or without vomiting, after intranasal glucagon administration [36%] vs. intramuscular administration [38%]) (Table 2).",35949,36352,True
3685700,13686,no significant difference,"Plasma concentrations of ghrelin were significantly higher under conditions of TSD, whereas plasma glucose did not differ between the conditions.",4956,5102,True
4177066,13780,significantly increase,"a statistically significant difference between groups in favor of the early group was found for the acquisition of new knowledge regarding the importance of early reading aloud (p < 0.001) and of infant socialization (p = 0.01, Fisher exact test).",25024,25272,True
5827476,13546,significantly increase,Mean DOA in Group S was 0.06 ± 0.172 h (3.6 ± 10.32 min) and that in Group B was 19.35 ± 8.64 h (P = 0.000).,4511,4636,True
3558647,13695,significantly decreased,The best time to laryngoscopy was predicted by measuring TOF and was found to be significantly longer in the C group (197 ± 53 s) than in the R group (102 ± 49 s) (P value < 0.05).,5343,5523,True
1553435,11535,significantly increase,Mean weight loss at 6 months was 5.6 kg (6.1%) following the 6 month clinical intervention and 3.4 kg (3.7%) and 2.7 kg (3%) at the 12 month and 24 month follow-ups. T,25309,25476,True
3511174,13610,no significant difference,"There were significant, or close to significant, short-term treatment effects in favour of group BT for muscle strength in injected muscles (elbow flexion strength, p = .08) and non-injected muscles (elbow extension and supination strength, both p = .05), without concomitant increases in muscle tone.",5229,5565,True
4590915,13809,significantly decreased,There was decrease in serum potassium in both the groups which was significant (P < 0.05) in Rhubarb group as compared to control.,15317,15468,True
3672778,12204,no significant difference,"PgR and Ki67 expression were significantly reduced with all treatments (means were -34% to -45%, and -75% to -85%, respectively; all P = 0.0001), with no differences between groups.",6553,6751,True
5737953,13691,significantly decreased,"For the further visits on Days 2 to 5 there was a significant difference in favor of propolis, reaching 89% versus 66% free of itching or burning (Figure 6), and 94% versus 74% free of tension and swelling (Figure 7) at Day 5 for propolis versus aciclovir (P < 0.001 based on Mann-Whitney U test).",24812,25227,True
5440059,13593,no significant difference,Most study participants reported nocturia at baseline; the number and relative percentage of participants reporting nocturia were similar between the groups and did not change over the course of the study.,21085,21292,True
4757000,13586,significantly increase,"Similarly, the comparison of scores achieved in I–QOL administered before and 6 months after the surgery revealed that the patients in the TOS group showed significantly better improvement (81.31% versus 69.28%, p=0.001) (Table-3).",19699,19969,True
1868017,13051,significantly decreased,"In women, significant differences in the changes between the groups were found in usual activities (p = 0.005) and discomfort/symptoms (p = 0.047).",5649,5797,True
4588430,13578,significantly decreased,"Telephone consultation had a mean cost of UK£35.41 per patient consultation compared with £51.12 for face-face consultation, difference £15.71 (95% CI 11.8–19.6; P < 0.001).",6066,6239,True
4733105,13605,no significant difference,"There was no significant effect of training group either on task accuracy or reaction time (P = 0.723 and P = 0.200, respectively).",44363,44562,True
4590915,13810,significantly increase,"There was significant increase in serum calcium (P < 0.01), decrease in TUP (P < 0.05), increase in TUV (P < 0.001), and increase in GFR (P < 0.001) after 12 weeks of treatment in Rhubarb group as compared to control group (Table 2).",15468,15825,True
4644318,13800,no significant difference,"Effective pain relief [numeric rating scale (NRS) < 3] was observed in 77.3% (95% CI: 67‒90.5%) of patients in PIL group and 74.2% (95% CI: 62.4 - 89.4%) of patients in the TF group (P = 0.34), at 4 weeks.",5300,5506,True
4649576,13540,significantly decreased,"Comparison of the severity of nausea and vomiting during the treatment days did not show significant difference between the three groups; however, the severity of nausea in placebo group was higher than that of the ginger and vitamin B6 groups during the treatment [Table 3].",13621,13935,True
5319516,13658,no significant difference,There was no significant difference in CK between the three groups before and after treatment (Table 4).,20452,20598,True
4687062,13554,significantly increase,The mean absolute change of the global LVEF was higher in the BMMNC group (placebo 1.1 SD 10.2 vs. BMMNC 9.5 SD 16.0) (Fig 1C).,36403,36583,True
3881817,13507,significantly increase,"Yet, in the 90 day period, the EC40TM group had only one leaked sample, in contrast with the five samples showing leakage in the 2% CHX group. EC40TM had significant differences when compared to the 2.5% NaOCl group and the group 0.2% CHX + 0.1% CTR.",20458,20730,True
1526611,11608,no significant difference,The overall incidence of adverse events was similar across treatment groups.,7538,7614,True
4756994,13345,significantly decreased,"The calculated cumulative tramadol consumptions at 24th hours per kilogram were 370.6 ± 121.6mg, 220.9 ± 92.5mg and 240.7 ± 110.4mg in groups 1, 2 and 3, respectively. We found significant differences in relation to tramadol consumption between groups 1 and 2 and groups 1 and 3 (one-way ANOVA test, p < 0.001).",19555,19867,True
4710815,13704,no significant difference,"Respimat had a similar mortality risk versus HH18 (vital status follow-up, HR; 95% CI R2.5: 0.87; 0.64 to 1.17; R5: 0.79; 0.58 to 1.07) with no significant differences in the risk and rates of exacerbations and severe exacerbations across treatment groups. Risk of MACE and fatal MACE was similar for Respimat versus HH18 (HR; 95% CI MACE R2.5: 0.73; 0.47 to 1.15; R5: 0.69; 0.44 to 1.08; fatal MACE R2.5: 0.57; 0.27 to 1.19; R5: 0.67; 0.33 to 1.34).",7295,7745,True
4736250,13886,significantly increase,"After controlling for potential confounders, the intervention group achieved a marginally significant improvement in the self-reported moderate intensity MET minutes per week (p = 0.049) relative to the control group.",28907,29141,True
5745479,13646,significantly increase,"Rash was only significantly more often reported by males (interaction term 3.72, p = 0.021; odds ratio in males 2.79 (95% CI 1.08–7.22) (Table 4).",14309,14534,True
5988794,13835,significantly increase,"In the primary analysis, the mean difference in iHOT-33 scores, adjusted for impingement type, sex, baseline iHOT-33 score, and centre, was 6·8 (95% CI 1·7–12·0) in favour of hip arthroscopy (p=0·0093).",21207,21410,True
3525560,12361,no significant difference,"The median parasite reduction ratios at 12, 24, 36, and 48 h (calculated as 100 minus the percentage reduction from the baseline level) were 0.93 (IQR: 0–2.98), and 0.0 (IQR: 0.0–0.0) in Arm1; 0.78 (IQR: 0.0–3.08), and 0.0 (IQR: 0–0–0.0) in Arm 2; 70.37 (IQR: 5.71–187.84), 0.8 (IQR: 0.0–7.14), 0.0 (IQR: 0.0–0.57) and 0.0 (0.0–0.0) in Arm 3.",40706,41048,True
3664320,13665,significantly increase,Median progression-free survival in Japanese patients was 12.1 months (95% confidence interval 8.6 to not estimable) for axitinib and 4.9 months (95% confidence interval 2.8–6.6) for sorafenib (hazard ratio 0.390; 95% confidence interval 0.130–1.173; stratified one-sided P = 0.0401).,7329,7630,True
4756994,13346,no significant difference,"Nevertheless, we did not find significant differences between groups 2 and 3 (one-way ANOVA test, p > 0.05).",19867,19975,True
3751456,12402,significantly increase,"At 6 months, weight loss was greater in the NGLCD group (−5.02 ± 3.43 kg vs. −4.1 ± 2.6 kg; p = 0.002) compared to the LFD group.",7476,7624,True
29053,13252,significantly decreased,"Total respiratory heat loss varied from 51 to 52 cal/min with the HH, from 100 to 108 cal/min with the hydrophobic HME, and from 92 to 102 cal/min with the hygroscopic HME (P < 0.01).",3828,4028,True
3525331,13140,significantly increase,"And there was significant difference in the proportion of patients with a reduction of migraine days by at least 50% between the CXDT-HFG group and the placebo group at follow-up period (83.7% versus 64.3%, P = 0.014) (Table 1; Figure 2).",25923,26258,True
3695249,13537,no significant difference,Pain scores and the total amounts of fentanyl administered via IV-PCA were similar in the three groups during 48 h after surgery (Fig. 2).,16799,16974,True
3751503,13653,no significant difference,Significant improvement in IKDC scores (P < 0.0001) as well as KT-1000 results (P < 0.0001) was noted over the 24-month period for both groups. IKDC or KT-1000 results were not significantly different between groups at any time point.,5074,5345,True
3738453,12109,significantly increase,"n addition, the blood caffeine level also increased only in the caffeine group (P = 0.008).",4251,4359,True
1852321,11664,no significant difference,"A significant increase in defecation frequency (NF: 3.5 pre versus 5.6/week post treatment; SF 3.6 pre versus 4.9/week post treatment) was found in both groups, but was not significantly different between the two formulas (p = 0.36).",4531,4764,True
5801514,12493,significantly increase,"Moreover, participants rated experts who used high amounts of MTJ to have higher competence (F1,96=37.54, P<.001, ηp2=.28],",7155,7348,True
5383744,11922,significantly increase,MS-EGF group showed statistically significant increase of dermal depth and density compared to EGF alone group after 4 and 8 weeks.,5380,5511,True
5985618,13756,significantly increase,The amount of bleeding in the LC group was found to be significantly less than in the RF group (P<0.05).,4504,4608,True
2797956,13602,significantly decreased,"However, for closed-loop phases, plasma insulin peak levels were significantly lower (29.7 ± 2.9 vs. 51.5 ± 8.4 mIU/l, P = 0.017) and the time to the plasma insulin peak was longer (79.9 ± 7.2 vs. 38.3 ± 7.2 min, P = 0.012).",28794,29053,True
4372550,13150,no significant difference,"The WEI JET significantly reduced successful tracheal intubation attempts compared to the LW group (1.0±0 VS. 1.21±0.4, p = 0.043). There was no difference in time taken for intubation and number of intubation attempts between LW group and DL group (Table 2).",29616,29959,True
4170701,13503,no significant difference,"Either at baseline or after 3-month exercise, no significant difference was observed between the two groups in terms of variables of pulmonary function test.",28263,28421,True
5333470,13399,significantly decreased,"In the patients of the dexmedetomidine group, compared to the control group, the pain scores at rest or at coughing during 48 h postoperatively were lower (P < 0.001),",5264,5448,True
3661555,13814,no significant difference,Quality of life and work ability improved statistically over time but did not differ statistically between groups.,7866,7980,True
1794469,11344,significantly decreased,"However, the incidence of coagulase-negative Staphylococci was significantly higher in the landmark group of patients compared with the ultrasound group (p < 0.05).",24289,24488,True
3634960,12450,significantly increase,Group A showed a significant increase in the initial claudication distance in the second test compared to the first test.,6281,6402,True
3668104,13750,significantly decreased,"Group A was significantly different compared to Group B and C (P < 0.05): at 90 min (Group A: 86.5 ± 9.2 min, Group B: 85.1 ± 9.6 min, and Group C: 71.7 ± 11.6 min); a",13316,13483,True
5440059,13592,no significant difference,"Using a one-sided Fisher’s exact test, no statistically significant differences between groups for UI at midpoint (.125, CI = [0.00, 0.360], p = .247) or final assessment (.25, CI = [0.00, 0.515], p = .068) were found.",27903,28156,True
4769147,13462,significantly decreased,"there was a significant difference in the maximal body weight loss (expressed in percent—minus 7.3% in CLF group and minus 8.4% in control group respectively, p = 0.002).",47934,48105,True
3664327,13829,no significant difference,"The MANOVA showed that OT (vs. placebo) had no effect on empathic concern, F(1, 90) = 0.16, p = 0.69, or personal distress ratings, F(1, 90) = 0, p = 0.99.",34285,34531,True
5827476,13547,significantly decreased,Cumulative requirement of tramadol in 24 h in Group S was 123.33 ± 43.01 mg which was significantly higher (P = 0.00) than Group B (23.33 ± 43.01 mg) [Table 2].,13821,14037,True
5030453,13600,significantly increase,"At the third visit, significantly more patients in groups B (64.29% P=.04) and C (70.73%, P=.007) confirmed use of the Internet for this purpose compared with group A (41.46%).",34962,35172,True
5788993,12693,significantly decreased,Crow’s feet photographic severity score was reduced significantly (p=0.05) by −15% with the creams in comparison with both baseline value (2.3±0.2 vs. 2.7±0.3) and value of the non-treated side after 3 months.,14026,14253,True
3707735,12035,significantly increase,"Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p < 0.05; Borg: p < 0.05; MRC: p < 0.001; BDI1: p < 0.05; BDI3: p < 0.03), and independence level in activities of daily living (p < 0.03); 2) improvement in quality of life in activity section (- 6.63 pt) and in total score (- 5.43 pt);",5306,5632,True
5511975,11688,no significant difference,The difference in TLC was not significantly different between the two groups before and after therapy.,4281,4384,True
1664572,11636,significantly increase,The control group's mean STAI-3 was 36.9 (95% CI 35.4 – 38.4) compared to 39.6 (95% CI 38.0–41.2) in the intervention group (p = 0.02).,31689,31824,True
4733100,13790,significantly increase,"Compared to the attention control, intervention participants had significantly increased odds of meeting the U.S. recommended guideline of ≥ 150 min/week of at least moderate-intensity physical activity at 12 months for the modified CHAMPS (odds ratio [OR] = 2.86; 95% CI: 1.03–7.96; p = 0.04)",5472,5766,True
5704406,12738,no significant difference,Mean duration of remission was similar in both groups 8.13 + 8.85 months versus 9.15 + 8.28 months (P = 0.963).,14710,14839,True
5435086,13816,no significant difference,"The mean (standard deviation) proportion of days in which high, marked and extreme beta-agonist overuse occurred without medical review within 48 h was 0·94(0·20), 0·94(0·15) and 0·94(0·17), and 0·92(0·19), 0·90(0·26) and 0·94(0·15) for single maintenance and reliever therapy and Standard regimens, respectively.",8137,8451,True
5976302,13660,significantly increase,"Compared to the control group, statistically significant improvement of the treatment group was noted in transfer and basic mobility measured by PODCI (10.6, effect size: 0.76, P = .048) and physical health assessed by PedsQL (12, effect size: 0.59, P = .011) at the 12-week follow-up.",28216,28535,True
3935224,12131,no significant difference,"Regarding QOL, the EQ-5D was significant (p = 0.019) and the QoL-AD (Quality of Life – Alzheimer's Disease) showed a positive trend (p = 0.06) when rated by care workers, although not when rated by the participants themselves.",5799,6062,True
5819581,13419,significantly increase,"However, in the group comparison analysis for the same variables between IPV group and HFCWO group, we observed a significant improvement in the IPV group in TLC and TLC% (p<0.03), RV and RV% (p<0.04), and DLCO, MIP, and MEP (p<0.01).",19748,20039,True
4028193,13767,no significant difference,"The probability of the remission based on K6 was not significantly different between the groups at the 3-month follow-up (RR = 1.02, p = 0.94)",71098,71240,True
4627615,13883,significantly increase,"In healthy subjects, the mean increase in serum 25(OH)D concentration was 4.06 (95 % CI 3.41, 4.71) ng/ml in soft gelatin capsule group and 8.0 (95 % CI 6.86, 9.13) ng/ml in buccal spray group after 30 days treatment (p < 0.0001).",5303,5534,True
1949842,11436,no significant difference,No statistically significant difference was found according to the infant feeding practice (p = 0.48).,34921,35040,True
57751,11283,significantly decreased,"Bezafibrate significantly reduced total cholesterol by approximately 8.0% and low-density lipoprotein (LDL)-cholesterol by approximately 9.0%, and increased high-density lipoprotein (HDL)-cholesterol by approximately 11.0% initially, falling to about 6.0% at 3 years.",3439,3707,True
5988794,13834,no significant difference,There were no significant between-group differences in SF-12 or EQ-5D-5L scores at 6 or 12 months after randomisation (table 2).Figure 2,55476,55675,True
5984011,11707,no significant difference,There was no significant difference among the three groups before the treatment (p=0.15) and four weeks after the treatment (p=0.77) in terms of total sexual function score.,30907,31081,True
5440036,13439,no significant difference,"No significant difference was found between the three groups, in terms of recovery time (P=0.076).",21036,21151,True
3707735,12034,significantly increase,"After 2 months of therapy (T1) the FFMI increased in the daily dietary supplementation group (+ 3.7 %) and decreased in the placebo group (- 0.6 %), resulting in a statistically significant (p < 0.001) treatment difference.",4946,5170,True
4990415,13862,significantly decreased,"GSLiM participants also achieved significant improvement in total weight self-efficacy score, negative emotions and physical discomfort subscales,",10440,10587,True
4745915,13839,no significant difference,"No differences regarding the absolute number of CD62L+, CCR5+, and CCR7+ cDC could be detected between the groups in the course of the 12-week time period",36267,36454,True
5055753,13482,no significant difference,"Mean ± SD of heart rate in the clonidine group was lower than that for the midazolam group, at 0 (P = 0.51), 30 (P = 0.24), 60 (P = 0.32), 90 (P = 0.088), 120 (P = 0.072), and 180 (P = 0.095) minutes, but it was not significant at these time points (Figure 3).",19892,20195,True
5096778,13867,no significant difference,There was no treatment group difference (P=0.6) with the number of capsules returned (placebo vs ibudilast [mean {SD}: 2.4 {2.4} vs 7.7 {15.6}]).,23016,23178,True
5805693,12499,significantly increase,"Despite higher meal insulin boluses with overestimation for both meals (9.2 [8.2–9.6] vs. 8.1 [7.3–9.1] U and 8.4 [7.2–10.4] vs. 4.8 [3.7–5.6] U; p < 0.05), mean glycemia, percentage of time in target range and glucagon infusion did not differ.",7155,7400,True
4990415,13860,no significant difference,"Systolic blood pressure, (mmHg)	128.6 (16.1)	129.1 (14.4)	0.712
Diastolic blood pressure, (mmHg)	83.0 (12.2)	83.4 (10.7)	0.774",57890,58366,True
4525725,13496,no significant difference,"94). There was also no difference in the average number of additional actions related to survey health risks taken by the GP (such as help plan changes to lifestyle, gave me information, organised a follow up appointment) between participants who received the generic versus tailored feedback (t(85) = 0.85, p = .40).",29080,29431,True
3634976,13746,significantly decreased,"However, these analyses suggested that the magnitude of the response was statistically significantly lower in MenACWY-TT recipients than in MenPS recipients in terms of VR rate for serogroup A and rSBA GMTs for serogroups A and C.",37631,37862,True
5030453,13599,significantly decreased,"During the second visit, only group B reported significantly fewer concentration issues than group A (P=.006).",34192,34319,True
3598524,13254,significantly decreased,"The median of overall hands-off time was significantly higher for endotracheal intubation (39.4s; 95% CI 34.0-44.9s) compared to Laryngeal tube (6.1s; 5.2-6.9s), Combitube (7.9s; 6.9-9.0s), LMA (10.2s; 8.6-11.7s), EasyTube (8.8s; 7.3-10.3s), and I-Gel (11.9s; 10.2-13.7s) (Table 1).",16695,17016,True
4360612,13449,significantly increase,75% of the surgery group vs. 27.3% of the NSM group had ODI improvement of ≥15 points (p<.0001).,48626,48722,True
88884,11182,significantly increase,Low tar cigarettes are safe .....................	93.0	96.7	p = 0.0004,32737,32876,True
1783667,11500,no significant difference,"UCLA Positive Summary Score
UC	2.95 (.60)	2.99 (.71)	3.00 (.77)	2.99 (.71)	30.11***	2.96a
MLP	2.85 (.73)	3.40 (.74)	3.28 (.74)	3.20 (.79)",47557,47975,True
1713262,11482,significantly increase,"In contrast, participants in the Cotrifazid group were reported shortness of breath significantly more often than did those in the mefloquine group (p < 0.01) (see Table 2 for details).",32984,33246,True
3590692,13574,significantly decreased,"The baseline mean scores of depression, anxiety and stress were not significantly different between the case and control groups. However, the scores in the case group improved significantly after the treatment (p < 0.05).",5307,5529,True
2365957,13453,no significant difference,"Fasting total/LDL/HDL-cholesterol changes-from-baseline were also similar,",5679,5754,True
2556743,13430,significantly decreased,"The number of postoperative complications per patient (1.4 ± 2.1 versus 3.9 ± 2.8, P < 0.05), as well as the median duration of mechanical ventilation (1 versus 5 days, P < 0.05) and stay in the intensive care unit (3 versus 9 days, P < 0.01) was also lower in group I.",5291,5620,True
2869037,12433,significantly increase,Time to recurrence within 48 h was better for F especially between 4 and 16 h (p < 0.05).,4761,4867,True
5878866,13874,no significant difference,The mean pain intensity score was 9.02 ± 1.32 in the TENS group and 8.95 ± 1.33 in the fentanyl group at baseline (P = 0.80).,6055,6197,True
4710815,13702,no significant difference,"Although the incidence of cardiac disorders was higher in the HandiHaler group (n=5 vs 2), the very small number of cardiac deaths, the small absolute risk difference and the wide CIs around the HRs, do not indicate any significant difference (table 2).",33037,33347,True
5735484,13417,significantly increase,Group II had better parental separation (P < 0.001) and sedation score (P < 0.001) compared to Group I and III.,4670,4819,True
3494213,11919,no significant difference,The level of serum leptin in middle-aged women did not change significant.,4225,4300,True
5834094,11728,no significant difference,"Perception accuracy of dot mapping was equivalent to colour mapping for both propagation direction (1.5 ± 1.8 vs. 4.8 ± 5.3°, P = 0.24) and focal source localization (1.1 ± 0.7 vs. 1.4 ± 0.5 mm, P = 0.88).",4754,4993,True
1821028,11433,no significant difference,Although triglyceride dropped by 13.72 mg/dl (6.3%) but this was not significant statistically (P-value: .222).,3957,4068,True
1550956,13667,significantly increase,. DrotAA treatment improved protein C levels by day 1 compared with placebo (P = 0.008),6380,6484,True
2921405,13776,no significant difference,"Overall, there was no effect of prebiotic and probiotic on diarrhea (6% reduction, 95% Confidence Interval [CI]: −1 to 12%; p = 0.08).",6932,7066,True
3493721,12546,no significant difference,"At week 48, AR rates in True, Sham, and Control were 40.0%, 9.1%, 18.2%, respectively, yet statistically no significant difference was seen between the three arms (Fig. 3).",18363,18572,True
4650105,11886,no significant difference,"The OsteoACTIVE rehabilitation programme revealed no significant effect on quadriceps strength,",5908,6004,True
3666925,13708,significantly decreased,"Morphine-induced postconditioning reduced postoperative peak cTnI release as compared to the control group (0.57 ± 0.15 versus 0.75 ± 0.20 ng/mL, p<0.0001).",5363,5520,True
5891985,13804,significantly decreased,"We found a significant reduction in waist circumference (92 ± 12 vs 88 ± 11 cm, P = 0.001) and body weight (81 ± 17 vs 78 ± 16 kg, P = 0.001), as well as BMI (28.63 ± 3.86 vs 27.67 ± 3.62 kg/m2, P = 0.001), with liraglutide treatment.",25557,25854,True
5985865,12689,significantly increase,The results revealed that the greatest significant percentage of change and subsequent improvement in pain and sign scores were recorded in the combined group.,3791,3950,True
5966929,13432,significantly increase,"The proportion of accurate trials with the participants with ASD in the intervention condition was greater than that for the participants with typical development, p < .001, and for the participants with ASD in the wait-list control condition, p < .001.",51635,51928,True
4925999,12746,significantly increase,"Overall, the study findings demonstrated that the level of dietary and medication adherence improved significantly in the participants of the intervention group who had received the nurse-led telephone follow-up intervention.",36179,36404,True
4210722,13830,significantly increase,"In Hamburg, significantly more vaccination certificates were submitted by the group which received the reminder card separately 4 days before the examination (IG3) compared to IG1 and IG2 (p = 0.04).",6454,6671,True
4745915,13837,significantly increase,"cortisol levels significantly increased in the trained group after the 12-week combined exercise program (P = 0.047, Table 2), while no change was observed in the sedentary control group.",31390,31635,True
88884,11187,significantly increase,Some people start to use tobacco because their friends do ...............................	95.6	97.5	p = 0.0223,33822,34001,True
3668608,12927,no significant difference,"Mean depression scores were not significantly different across the 3 programs at posttest (IPT vs MoodGYM: 2.01, 95% CI –0.32 to 4.34, P=.09, higher for IPT; CBT vs MoodGYM: 0.22, 95% CI: –2.17 to 2.61, P=.86, higher for CBT).",36930,37193,True
3488187,12206,significantly increase,More patients assigned erlotinib had rash at any time and of any grade than did those assigned placebo (56% [188 of 334] vs 15% [46 of 313] p<0·0001).,22265,22433,True
2699714,13775,significantly decreased,From baseline to week 24 insulin dose decreased 18% in the etanercept group compared with a 23% increase in the placebo group (P < 0.05).,5796,5954,True
5986449,12902,significantly increase,Changes in the AA of the left eye after rest in non-presbyopic subjects younger than 45 years at weeks 4 and 8 significantly improved in the “Sunrouge” group (n = 8) compared to the placebo group (n = 10) (Figure 3A).,20721,21031,True
3258705,13671,no significant difference,"Although the serum progesterone concentration was higher in the oestradiol group in comparison to the control group on day 7, 10 and 12 after embryo transfer, these differences were not statistically significant.",6230,6442,True
2365983,13717,no significant difference,"Although daily and total morphine requirement in the TLRP was lower compared with the HAL-RP and ORP groups, this difference was not statistically significant (Fig. 1). Figure 1",23269,23507,True
4525725,13497,significantly increase,"Significantly more participants who received the tailored feedback reported showing this to their GP than those who received the generic feedback, Fisher’s exact χ2(2, N = 70) = 7.30, p = .03.Table 2",27454,27744,True
3611074,13467,no significant difference,"There was no significant difference in the median preoperative anxiety score using mYAS between two groups in the pediatric ward (median: 23.3 and range: 23.3-23.3 in the control group vs. median 23.3 and range: 23.3-30.0 in the ketorolac group, P = 0.178)",15459,15715,True
3707921,13011,no significant difference,"Although the between-group difference in the mean reduction of completion time did not reach statistical significance, t(33) = 1.61, p = 0.12, the effect size (0.55) is at the medium level.",50308,50532,True
3636850,13634,significantly decreased,"The mean Streptococcus mutans and Lactobacillus was found to be significantly lower in the fluoridated group at 3, 6, and 12 months time interval (P < 0.05).",11464,-1,True
3483184,12247,significantly decreased,There was a statistically significant difference in peak plantar pressure between the DH Pressure Relief Shoe™ compared to both the control shoe (p = 0.002) and participants’ standard shoe (p = 0.001). The DH Pressure Relief Shoe™ decreased plantar pressures by 51% compared to the control shoe and by 43% compared to participants’ standard shoe.,4940,5321,True
5858078,12193,significantly decreased,"The repeated measures analysis revealed that the area of WSLs decreased significantly between T1 and T2 in all the study groups (P< 0.05) [Figure 2]. However, between T2-T3 and T3-T4 time points, a significant reduction in the area of WSLs occurred in MI Paste Plus and Remin Pro groups (P< 0.05), whereas the control group revealed no significant improvement in this aspect (P > 0.05) [Figure 2].",21207,21738,True
5438446,12300,significantly decreased,"The median number of visits to general practitioners for EDGE versus usual care were 4 versus 5.5 (P=.06) and to practice nurses were 1.5 versus 2.5 (P=.03), respectively.",9905,10110,True
5093191,13787,significantly increase,"Compared to the control condition, men in the intervention significantly improved their 6-min walk distance (M diff = 49.98 m, p adj = 0.001), leg strength (M diff = 21.82 kg, p adj = 0.001), chest strength (M diff = 6.91 kg, p adj = 0.001), 30-s sit-to-stand result (M diff = 3.38 reps, p adj = 0.001), and reach distance (M diff = 4.8 cm, p adj = 0.024).",4872,5509,True
57749,11398,significantly decreased,Eptifibatide reduced the incidence of death or MI in the PURSUIT trial by 1.5% (15.7% versus 14.2%; P = 0.042) at 30 days [6].,18155,18336,True
5038098,11956,no significant difference,"At 24 weeks 68.64% (Group A) and 56.03% (Group B) patients were acne free, which at the end of 36 weeks decreased to 50.84% and 39.65%, respectively (P 0.51) [Table 6].",16099,16323,True
4590915,13811,significantly decreased,"There was significant increase in serum calcium (P < 0.01), decrease in TUP (P < 0.05), increase in TUV (P < 0.001), and increase in GFR (P < 0.001) after 12 weeks of treatment in Rhubarb group as compared to control group (Table 2).",15468,15825,True
4967511,12536,no significant difference,"We could not detect any statistically significant differences between groups for the outcomecategories Emotional and Social Experience in school (p = 0.22 to 0.78), Physical Activity, Well-being, and Attention Performance.",6000,6291,True
88884,11188,no significant difference,Smoking is relaxing ..........................	89.9	89.4	N.S.,34036,34166,True
4595873,12663,no significant difference,"At 12 months' of follow-up, PRP and HA treatments offered similar results.",4260,4334,True
4579488,13261,no significant difference,"The RRT is insignificantly reduced by 2.77% (placebo), 5.83% (N. Sativa), 7.21% (Garlic) and 12.64% (CoQ10) from the pretreatment values [Table 1].",11383,11587,True
1513247,11393,significantly decreased,Symptom severity for all symptoms (except constipation) were in the expected direction of baseline>placebo>experimental condition. Symptom improvement was in the range 4 – 6%.,4421,4596,True
3636841,12307,significantly increase,The mean preparation time for group A was 4.7 Mins (minutes) and group B was 17.96 min s (P < 0.001).,3935,4056,True
3747889,13707,no significant difference,There were no differences in the primary and secondary outcomes between the n-3FA supplement and placebo groups.,8239,8351,True
5440036,13437,no significant difference,Vomiting scores among all groups were similar during all intervals (P>0.05).,4779,4875,True
3606612,13640,no significant difference,The TSAT at 6 months was not different between the two groups {p = 0.82},4930,5002,True
5769198,12117,no significant difference,"Other domains of WHO-QOL-BREF, PANAS, and HADS did not reveal any significant between-group differences.",5317,5421,True
5873437,13590,significantly increase,"IL1Ra levels were elevated compared with baseline significantly at study day 3, 5, and 7 in ELAD patients (P < 0.05), but not in controls.",84056,84214,True
3714385,13652,no significant difference,There were no significant differences in the 3-MH/Cr values between the 2 groups at any time point.,5302,5402,True
1224861,11630,no significant difference,"Differences between the two groups were nonsignificant with regard to number of grafts per patient, mean duration of surgery, anesthesia and operating room time, length of stay intensive care unit (ICU) and rate of postoperative atrial fibrillation",3956,4204,True
3714385,13650,no significant difference,"HOMA-IR varied within normal limits before induction of anaesthesia, 60 min after the start of surgery, and at the start of skin closure, with no significant differences between the 2 groups.",18720,18911,True
3872585,11757,significantly increase,Results suggest that morphine is more likely to cause symptoms of dizziness and arterial hypotension.,15677,15778,True
2826289,13487,significantly increase,"Subjects who received Bacillus coagulans GBI-30, 6086 experienced borderline statistically significant improvement in the Patient Pain Assessment score (P = .052) and statistically significant improvement in Pain Scale (P = .046) vs placebo.",4237,4529,True
3757635,13565,no significant difference,No significant intraoperative or post-operative complications were noted.,4040,4113,True
1913939,13520,no significant difference,The ANCOVA analyses for reported weight indicated that there was no significant differential change in weight between the two groups.,44255,44389,True
3531427,11743,no significant difference,"Noteworthy, inhalation of high dose iloprost seemed not to influence VO2 peak (p = 0.92).",30859,30960,True
3686162,13154,no significant difference,"The intervention had no effect on delirium duration, severity, discharge destination or length of stay.",8105,8208,True
4218764,13828,significantly decreased,"There was also a significant difference in pain scores (numerical rating scale) between groups, where the PVB group had lower scores than did the control group at rest and with coughing for the first 24 hours (P < 0.001).",5891,6132,True
5819580,12937,no significant difference,"The time to first use of rescue medication was significantly longer versus placebo with meloxicam IV 60 mg (P<0.05), but not with meloxicam IV 30 mg doses.",5782,5954,True
5706840,13085,significantly increase,"The median progression-free survival for the combined populations with mid or high miR-31-3p expression was shorter in the CTX versus the CT arm (26.7 months versus 12.3 months, HR=2.28 95%CI 1.27; 4.09 p=0.006).",6107,6320,True
5244530,13819,significantly increase,"However, significantly more patients in the intervention group continued antidepressants until the 6 month follow-up (86/125 vs 78/133, p < 0.05).",8637,8801,True
3687098,13569,significantly increase,The incidence of the composite endpoint of rash was higher in the sitagliptin group compared with the non-exposed group (Table 4).,46831,47003,True
4590915,13808,significantly increase,"There was significant increase in serum calcium (P < 0.01), decrease in TUP (P < 0.05), increase in TUV (P < 0.001), and increase in GFR (P < 0.001) after 12 weeks of treatment in Rhubarb group as compared to control group (Table 2).",15468,15825,True
5866733,13631,significantly increase,Lactate levels at 24th and 48th postoperative hours were significantly higher in Group 1 when compared to Group 2 (p<0.05) (Figure 3).,16258,16474,True
5771057,11691,significantly decreased,"A repeated measures analysis of variance revealed that task complexity significantly affected the performance measures of auditory accuracy, visual accuracy, and processing speed.",4082,4261,True
3682309,13844,no significant difference,"Duration RRT received, hrs	130 ± 222	128 ± 142	0.87",30495,30609,True
3641298,13071,significantly decreased,"Overall (n = 108), pain intensity was significantly improved at 1 week, including worst pain (7.3 to 5.7, P < 0.01) and average pain (4.6 to 3.8, P < 0.01).",5638,5849,True
5850768,13736,no significant difference,"In summary, the safety profile of SB2 remained relatively consistent with previously reported data (up to 30 weeks) and was comparable to that of INF. Table 1",27811,28052,True
5819581,13421,significantly decreased,Only a slight significant change in neutrophil count was observed in the IPV group compared to HFCWO group (p<0.05).,20402,20535,True
5866733,13628,no significant difference,"Serum BUN levels demonstrated no significant difference in the preoperative period (17.6±4.99 vs. 18.6±4.72, for Group 1 and 2, respectively, p>0.05) and after cardiopulmonary bypass (17.1±4.61 vs. 19.6±8.56, for Group 1 and 2, respectively, p>0.05)",15606,15893,True
3558645,11831,no significant difference,"Systolic, diastolic blood pressures and heart rate did not show any significant differences before inducing anesthesia, after intravenous injection of propofol, just before intubation, immediately after intubation, 1, 2, 3 and 5 minutes after intubation, between the two groups.",12315,12593,True
1579211,11793,significantly increase,The total incision length was 12.9 cm versus 8.9 (p < 0.05) in the SaphLITE and Clearglide groups.,4917,5016,True
3505775,12687,significantly decreased,"The mean skin erythema in eczematous lesions on the flexor surface of the forearm in group A decreased significantly from 425.6±75.8 to 379.6±91.4 AUs, compared to the baseline (p=0.0025).",16245,16451,True
5729492,12668,significantly decreased,"The feeling of hunger/satiation was significantly improved in the control group compared with the feedback group (−5.2 vs. 2.9; 95% CI, 0.9 to 7.6) (Table 3).",48558,48774,True
3666925,13709,significantly decreased,"Morphine-induced postconditioned patients had lower peak inotropic score (5.7 ± 2.4 versus 8.4 ± 3.6, p<0.0001) and shorter duration of mechanical ventilation as well as ICU stay (20.6 ± 6.8 versus 28.5 ± 8.3 hours, p<0.0001 and 40.4 ± 10.3 versus 57.8 ± 15.2 hours, p<0.0001, respectively),",5520,5811,True
4753023,13649,significantly increase,"Ferritin level, μg/L	28.5 ± 9.3	27.22 ± 12.96	0.04",19532,19770,True
4756994,13344,no significant difference,"owever, the reduction of postoperative VAS scores was in all times similar among the groups (repeated measured variance analysis, test, p = 0.466) (Table-2).",13275,13474,True
5850960,12697,no significant difference,"Similarly, while the trial was not powered to detect differences in overall survival, no significant differences in overall survival between study arms were noted (Fig. 6b).",36730,36943,True
5878866,13876,significantly increase,The use of analgesic drugs in the TENS group was significantly higher than the fentanyl group (P = 0.01).,6477,6599,True
3664406,13558,no significant difference,"There were no differences in overall satisfaction scores, as assessed by a 10-cm visual analog scale.",58767,58868,True
5878866,13875,no significant difference,"Repeated measures analysis of variance indicated that there was no significant difference on overall pain scores between the two treatment groups adjusted for age, BMI, total analgesia used, and baseline pain score (F (1, 74) = 1.44, P = 0.23).",6198,6476,True
2836833,13760,significantly increase,Fecal fat loss expressed as percent of fat intake was significantly higher with 1500 mg (high-Ca) compared to 500 mg (low-Ca) calcium intake per day (mean: 3.0%; the 95% CI: 2.3 to 3.7%; P <0.001) independent of calcium source and lactose digestion status.,4734,5007,True
3744465,12516,no significant difference,"For PSPC and placebo groups, 3-d averages during 7.5 h running for heart rate (HR) were 152±15.3 (82.1±3.6% HRmax) and 151±9.7 bpm (84.2±3.6% HRmax), respectively, (P = 0.930),",48131,48329,True
5805261,13749,no significant difference,The 1-year and 2-year LTP free survival rates were 93.9% and 84.3% in the SB-RFA group and 94.4% and 88.4% in the SM-RFA group (p = 0.687).,16111,16267,True
3599931,11853,significantly decreased,"Weight (kg)
81.1 (14.3)
80.7 (14.1)
84.3 (17.8)
84.7 (17.9)
0.093",31083,31388,True
4360719,13457,no significant difference,"There was no statistically significant difference between the groups for the change in CRQ dyspnoea score (primary end point) at 12 months which amounted to 0.19 (−0.26 to 0.64) units or other domains of the CRQ. There was no difference in the ESWT duration (−10.06 (−191.16 to 171.03) seconds), BMI, body fat, EQ5D, MET-minutes, activity rating, HADS, exacerbations or admissions.",6874,7255,True
5866733,13630,significantly decreased,"Serum BUN levels demonstrated no significant difference in the preoperative period (17.6±4.99 vs. 18.6±4.72, for Group 1 and 2, respectively, p>0.05) and after cardiopulmonary bypass (17.1±4.61 vs. 19.6±8.56, for Group 1 and 2, respectively, p>0.05) whereas the differences were significant at 24th postoperative hour (18.7±4.36 vs. 24.4±9.52, for Group 1 and 2, respectively, p<0.05) and 48th postoperative hour (19.8±5.42 vs. 24.9±10.90, for Group 1 and 2, respectively, p<0.05) (Figure 2).",15606,16258,True
5668343,12976,no significant difference,"Overall survival	All	0.91	(0.68–1.23)	0.54	
AIB1 Low	0.91	(0.60–1.37)		0.99
AIB1 High	0.91	(0.59–1.41)",47923,-1,True
88884,11181,significantly increase,(2) Smokers have yellow teeth and fingers ............	72.0	96.5	p = 0.0313	95.1	p = 0.0313,23492,23698,True
88884,11181,significantly increase,Smokers have yellow teeth and fingers ............	76.9	96.7	p < 0.0001,32559,32699,True
5873437,13588,no significant difference,Mortality differed minimally between subjects receiving between 72 and 120 hours (12/37) and completing 120 hours (17/45; 32.4% versus 37.8%).,76274,76416,True
5633094,12120,significantly decreased,"In both groups, MIP increased after the training; however, the increase was significant only in the EIMT group when the value before training was compared with that after training (P < 0.017).",21477,21669,True
4727391,12016,no significant difference,"There were no significant differences in first attempt at successful insertion (LM, 94.4 % vs. ETI, 90.6 %), insertion time (LM, 7.58 ± 1.16 s vs. ETI, 7.89 ± 1.52 s), Apgar score at 1 and 5 min, response time, ventilation time, successful resuscitation (LM, 86.1 % vs. ETI,  96.9 %), and adverse events (LM, n =3 vs. ETI, n =4) between groups.",5325,5703,True
5863299,13726,significantly increase,"The treatment group demonstrated better signs of clinical efficacy, including left ventricular ejection fraction, higher nitric oxide levels, and lower levels of endothelin-1 (ET-1) and von Willebrand factor (VWF).",5063,5277,True
5055753,13479,significantly increase,"The percentages of patients in the calm and sedated scale were significantly higher in clonidine group (35 and 42.5%, respectively), compared to the midazolam group (17.5 and 17.5%, respectively) (P = 0.042, 0.029; respectively).",4900,5130,True
4307366,12087,no significant difference,"None of the patients had phenylalanine more than 10 mg/ dl during treatment, and the mean serum phenylalanine of the patients was not significantly different during treatment with the two drugs (p = 0.537).",15574,15780,True
5737953,13690,significantly decreased,"Overall, patients in the aciclovir group had more severe tension and swelling than patients in the group using propolis (P = 0.042 based on Mann-Whitney U test; data not shown).",24583,24794,True
3681405,13683,no significant difference,"No statistical difference in PFS was seen between the two arms, with a HR of progression of 1.135 (95% CI, 0.855–1.506). The median PFS time was 42.21 months in the preoperative chemotherapy arm and 45.67 months in the surgery-alone arm (log-rank P = 0.38).",15617,15891,True
1174877,11596,significantly decreased,"Telmisartan, but not losartan, significantly (p < 0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic.",5194,5375,True
5843211,12038,no significant difference,"Within WL, the ECR-R scales did not change from pre to post (anxiety: Mpre = 3.58, SDpre = 1.14 vs. Mpost = 3.59, SDpost = 1.16; t(53) = .29, p = .77; avoidance: Mpre = 3.08, SDpre = 1.04 vs. Mpost = 3.12, SDpost = 1.12; t(53) = -.03, p = .987).",56561,57099,True
3659039,12559,significantly increase,"Erythrocyte EPA did not change significantly in the control group (Figure 2), but increased in the treatment group late in the infusion period (P < 0.005) (Figure 2).",20724,20968,True
3634264,13832,no significant difference,"This study showed that after one month of L-carnitine or placebo therapy there was no significant improvement in flow mediated dilation (p = 0.80 and p = 0.59, respectively) or decrease in carotid intima-media thickness (p = 0.12 and p = 0.50, respectively).",4849,5107,True
5891985,13806,significantly decreased,"At the same time, the differences before and after liraglutide treatment in 120 min of NEFA (− 32 [− 96, − 5] vs 5 [− 35, 38] µmol/L, P = 0.033) and AUCins (738 [451, 1118] vs 594 [357, 1216] mIU/L, P = 0.014) were remarkably enhanced compared to that of the metformin therapy.",6581,6893,True
5807510,13721,significantly decreased,"Median age at diagnosis (25 days [range 14–90] in cases vs. 130 days [range 37–451] in controls) and median time to diagnosis (13 days [range 1–84] in cases, vs. 107 days [range 21–429] in controls) were significantly less in cases than controls (p = 0.04).",10408,10683,True
4734805,13732,no significant difference,"The central retinal thickness did not show significant changes after treatment when compared to baseline as follows: in the bromfenac group (247.2±32.9 vs 252.0±24.9 μm; P=0.958) and in nepafenac group (250.8±34 vs 264.0±34.1 μm; P=0.137), respectively.",5727,6014,True
5066860,13454,significantly decreased,"After the NUT period, participants showed a significant reduction in MRS score (18.4±5.4) in comparison to baseline (28.4±5) and the placebo period (28±5.2) (P<0.0001 for both comparisons).",5285,5492,True
3687883,13120,significantly decreased,"The postoperative nausea and vomiting (PONV) rate after 1-2 h in the recovery room, after 2-12 and 12-24 h in the ward in placebo, and both groups of cetirizine and ondansetron were 50%, 21%, and 11%, respectively while the difference was significant (P value < 0.05).",4508,4794,True
1915612,11322,no significant difference,"After 12 weeks there was no significant difference between the two treatment groups in decrease of neck pain intensity on VAS (−7.0 mm, 95% confidence interval (CI) [−20.7 to +6.7]), mean number of neck pain days (−1%; 95% CI [−15% to +13%]), neck pain hours per day (−0.14; 95% CI [−3.0 to +2.7]), days on which symptomatic treatment was taken (−0.7%; 95% CI [−15% to +13%]) number of analgesics taken per day (−0.14; 95% CI [−0.6 to +0.4])",3212,3653,True
5732479,12173,no significant difference,"Neither total leukocyte counts nor numbers of mononuclear cells and neutrophils in nasal wash were affected by Fluenz vaccination, and no differences between groups were observed (Figure 11).",47721,47950,True
5057363,12274,no significant difference,"There were no between‐group differences in ACR20, ACR50, and ACR70 response rates.",7104,7186,True
3682309,13846,no significant difference,"Prescribed dose delivered, %	84.7 ± 16.3	87.8 ± 13.7	0.73",31248,31368,True
4173571,13541,significantly decreased,We found that the incidence and number of vomiting episodes and RAE required were significantly low in Group G and O compared with Group D; P < 0.05.,4760,4926,True
31579,13604,significantly decreased,"NO inhalation, in contrast, lowered mean pulmonary artery pressure (from 26 ± 1.9 to 23.9 ± 1.7 mmHg, P < 0.01), pulmonary vascular resistance index (from 314 ± 37 to 273 ± 32 dynes/cm5/m2, P < 0.05) and central venous pressure (from 8.2 ± 1.2 to 7.3 ± 1.1 mmHg, P < 0.02).",4420,4775,True
4757000,13585,significantly increase,"The comparison of scores achieved in ICIQ-SF administered before and 6 months after the surgery revealed that the patients in the TOS group showed significantly better improvement when compared to patients in the single-incision sling group (76.20% versus 64.10%, p=0.001).",19425,19698,True
1386666,11542,significantly decreased,"here were no statistically significant differences between the treatments for the average or maximum/minimum values for any of these variables, with the exception of heart rate, for which budesonide/formoterol had a lower maximum value (mean of 91.6 beats per minute) than formoterol (mean of 94.3 beats per minute; p = 0.026).",30630,30957,True
4525725,13495,no significant difference,"The mean number of topics discussed did not differ between those who received the generic (M = 2.87, SD = 2.39) versus the tailored feedback (M = 2.83, SD = 2.28; t(85) = 0.08, p = .94).",28796,29085,True
1797029,11308,no significant difference,There was a trend toward a shorter median time to treatment failure among women with HER2-positive tumors (2.3 versus 4.2 months; P = 0.067).,6931,7090,True
3881817,13509,no significant difference,No significant differences were observed between the 2.5% NaOCl group and the 2% CHX group or 0.2% CHX + 0.1% CTR.,20737,20852,True
4753023,13647,significantly increase,The mean Hb concentration was 12.05 ± 0.9 in the experimental and 11.94 ± 0.6 in the placebo group; this different was significant (P = 0.03),15431,15572,True
5883519,12470,significantly increase,"At the 3-month visit, there was a significant increase in IGF-1 in the rhGH treatment group compared with the control group (587.35 ± 271.74 vs. 345.60 ± 131.75 ng/mL, P = 0.001) (Table 2). At the 6-month visit, IGF-1 level increased during rhGH treatment, in comparison with the control group (702.91 ± 246.03 vs. 348.3 ± 131.93 ng/mL, P < 0.001) (Table 3, Fig. 2b).",30036,30561,True
4526972,12454,significantly increase,"The intervention group already showed significantly better adherence to temporal specifications than the control group at t1 (67.6%, SD 21.4 vs 43.3%, SD 23.4; P<.001),",36139,36335,True
5891985,13807,significantly decreased,"The levels of sVCAM-1 dramatically decreased after 8 weeks of liraglutide treatment (503 ± 182 vs 382 ± 131 ng/ml, P = 0.046) compared to that of the metformin treatment group.",6387,6580,True
1550249,11575,significantly decreased,"These cycles including oocytes with fragile zonae also exhibited significantly lower rates of compaction (23.8% versus 51.5%, P = 0.036), with a reduced blastocyst formation rate that also approached statistical significance (15.3% versus 31.8%, P = 0.084).",26663,26920,True
3598394,12145,significantly increase,"At 20 months, quality of life had increased by 0.08 units more in the intervention group than in the control group (P = .04),",5204,5347,True
1865087,11219,significantly decreased,"In the experimental group, vitamin C supplementation was significantly associated with both resistin concentration reduction (from 4.3 ± 1.5 to 2.9 ± 0.8 ng/ml; 95% confidence interval [CI] −1.87, −1.03) and ascorbic acid level increase (from 9.4 ± 2.9 to 19.0 ± 5.2 mg/l; 95% CI 7.9, 11.2).",5896,6188,True
5654748,13473,no significant difference,"The Web 2.0 group had a significantly greater average number of days per week with a step comment in comparison with the Web 1.0 group at 0–3 months; however, this was no longer statistically significant at 3–12 and 12–18 months.",39914,40144,True
29047,11555,significantly decreased,"Requirements for morphine were reduced by half in patients receiving dexmedetomidine while intubated when compared with placebo (0.011 ± 0.02 versus 0.022 ± 0.02 mg/kg per h; P = 0.024), and this morphine-sparing effect of dexmedetomidine was even more pronounced during the extubation period (0.003 ± 0.004 versus 0.008 ± 0.006 mg/kg per h; P= 0.040; Fig. 4).",20174,20606,True
4627615,13884,significantly decreased,"In healthy subjects, the mean increase in serum 25(OH)D concentration was 4.06 (95 % CI 3.41, 4.71) ng/ml in soft gelatin capsule group and 8.0 (95 % CI 6.86, 9.13) ng/ml in buccal spray group after 30 days treatment (p < 0.0001). In patients with malabsorption disease, the mean increase in serum 25(OH)D concentration was 3.96 (95 % CI 2.37, 5.56) ng/ml in soft gelatin capsule group and 10.46 (95 % CI 6.89, 14.03) ng/ml in buccal spray group (p < 0.0001).",5303,5762,True
3258705,13670,no significant difference,There were no significant differences between the two groups in LH levels measured on different days,14364,14464,True
34516,11539,significantly decreased,"Following oral methionine the AUC of change in endothelial-dependent FBF from baseline was significantly reduced compared to placebo, (31.2 arbitrary units [22.1-40.3] vs.46.4 arbitrary units [42.0-50.8] vs. p < 0.05 vs. Placebo, Figures 1 &2, Table 1).",17299,17672,True
4889182,13890,no significant difference,"Examining 7‐day page views (Table 3), there was similarly no difference in number of page views in the social media group (330.5) compared with the control group (268; P=0.17).",34447,34699,True
5599826,13424,significantly decreased,"However, eye close center of pressure (EC COP-x), eye open standard deviation-x (EO SD-x), and eye open height of ellipse (EO HoE) were only significantly decreased in the AR group.",11738,11919,True
2826289,13490,no significant difference,"For the HAQ individual disability scores, the ability to walk 2 miles was marginally significant (P = .072) and the ability to reach was not quite significant (P = .11) (Table 2).",17324,17576,True
1783850,11220,significantly decreased,"In the ModHT group, non apoptotic non necrotic cells (annexin negative, PI negative) decreased after CPB, while early apoptotic (annexin positive, PI negative) and late apoptotic or necrotic (PI positive) cells increased.",5045,5267,True
5858078,12195,significantly decreased,"The repeated measures analysis exhibited that the two experimental groups experienced significant reduction in the color difference between sound and demineralized parts of enamel throughout the experiment (P< 0.05), whereas the improvement in the control group was not statistically significant (P > 0.05) [Figure 4].",23479,23874,True
1976842,11244,no significant difference,The overall 5 year survival was 93% with no statistically significant difference between the two treatment groups (P = 0.54).,3390,3516,True
4236282,11769,significantly decreased,LSD post-hoc analyses showed that NPC BDI scores at post-treatment assessment were significantly lower when compared to UC (p=0.009) but not MIC (p=0.195).,26179,26368,True
5866333,13742,significantly decreased,"GHR blockade decreased free insulin–like growth factor‐1 (P=0.04 versus sitagliptin alone) and increased stimulated GH (P<0.01), but decreased vascular resistance (P=0.01)",8220,8515,True
4990415,13863,significantly decreased,"Total WEL score	-1.77 (1.45)	0.45 (1.19)	8.76 (3.05, 17.47)b	0.045	0.003",106013,106576,True
1174877,11598,significantly decreased,"Compared with losartan, telmisartan reduced FPG by 8% (p < 0.05), FPI by 10% (p < 0.06), HOMA-IR by 26% (p < 0.05) and HbA1c by 9% (p < 0.05) as shown in figure 1.",17764,17988,True
3747889,13706,significantly increase,"For the insulin glargine arm of the study, we observed a statistically nonsignificant reduction in CIMT progression for the primary outcome and significant differences, favoring insulin glargine therapy for the secondary CIMT outcomes.",27186,27421,True
3672718,13789,significantly increase,"A survival analysis of these 288 patients confirmed the advantage of E-CMF over CMF observed in the main trial [2] with HR: 0.57; 95% CI 0.37 to 0.86; P = 0.006 and HR: 0.64; 95% CI 0.41 to 1.01; P = 0.05 for RFS and OS, respectively.",17097,17403,True
3664406,13557,no significant difference,"Secondary outcomes comprised changes in stratum corneum hydration, skin surface pH, clinical observations of the skin, and maternal views.",5844,5982,True
3664406,13557,no significant difference,No significant differences were found in secondary outcomes.,6345,6405,True
3713945,12587,significantly decreased,"However, exercise duration was shorter when one’s more capable partner gave verbal encouragement (n=55) than when s/he did not (n=25) (a mean difference of 31.14s).",7618,7782,True
4644316,12347,no significant difference,"The adverse side effects such as vomiting, nausea, and hiccups in the experimental group was less than the control group, though this difference was not significant (P = 0.54).",5634,5810,True
4809147,12704,significantly increase,Spiromax was associated with a greater level of device mastery compared with Easyhaler or Turbuhaler; 37.5% of participants were able to use Spiromax with no errors in step 1 (intuitive use) compared with 0% with Easyhaler (p<0.001) and 9.2% with Turbuhaler (p<0.001; table 1).,21449,21789,True
4232915,13042,significantly increase,"Mean DLQI score improved significantly from baseline at week 12 in patients receiving liarozole 75 mg vs. patients receiving placebo [mean (SD) change, −4·3 (6·0); P = 0·014].",31657,31867,True
4210722,13831,no significant difference,"Overall, the use of a reminder card had a positive but not significant effect as 89 % (185/209) of participants who received the reminder card submitted vaccination data versus 81 % (84/104) of participants who did not receive any reminder card (p = 0.06).",6818,7091,True
1891439,11579,significantly increase,"Overall failures (acute treatment failure plus relapse plus death) were 29 in number (Figure 1). Overall failure rate at 1 month was estimated as 37.6% (95% CI = 27.14% – 50.2%) in the cefixime group and 3.5% ( 95% CI  = 2.2%–11.5%) in the Gatifloxacin group (HR[95%CI] = 0.084[ 0.025–0.280], p<0.0001) ( Figure 5).",42622,43044,True
5769191,13620,significantly increase,"There was a significant increase in the rate of clinical pregnancy in the intervention group, compared to the control.",5030,5149,True
3747889,13705,no significant difference,"Compared with standard care, insulin glargine reduced the primary CIMT outcome, but the difference was not statistically significant (difference = 0.0030 ± 0.0021 mm/year; P = 0.145) and significantly reduced the secondary CIMT outcomes (differences of 0.0033 ± 0.0017 mm/year [P = 0.049] and 0.0045 ± 0.0021 mm/year [P = 0.032], respectively). There were no differences in the primary and secondary outcomes between the n-3FA supplement and placebo groups.",7843,8351,True
5807625,12628,no significant difference,"Type of varnish	ΔWS area (mm2)a,b	ΔΔF (%)b,c
TiF4	0.01 (–9.15 to 1.19)	–1.29 (–16.30 to 4.74)
NaF	0.17 (–2.38 to 1.47)	–0.55 (–5.80 to 6.10)
Placebo	0.19 (–1.14 to 4.36)	–0.23 (–5.17 to 5.10)",31252,31920,True
5807625,12628,no significant difference,No differences between the treatments have been detected at the first month so far (P>.05).,8904,9012,True
3575612,13493,significantly decreased,There was a significant 3.6% reduction in bicarbonate in the high-dose group versus placebo (P = 0.02) with a similar trend in both low-dose groups,13314,13478,True
3575612,13493,significantly decreased,There was a significant 3.6% reduction in bicarbonate in the high-dose group versus placebo (P = 0.02) with a similar trend in both low-dose groups.,13314,13479,True
3560577,13679,no significant difference,"The mean time for pH >4 and pH >6 with lansoprazole was shorter than with pantoprazole on day 1, but the difference was not statistically significant (109.61±32.15 min vs. 153.42±29.36 min, P=0.3304 for pH 4; and 211.93±39.18 min vs. 288.43±35.79 min, P=0.1706 for pH 6).",20468,20813,True
5985618,13757,no significant difference,No significant difference was found between the groups regarding duration of procedure (P=0.157).,4609,4706,True
3269572,12107,no significant difference,"There were no clinically significant changes in clinical laboratory changes, vital signs, ECG or at physical examination.",29054,29175,True
